

List of Publications

Before the year 2000

1. Riley JP, Pestano GA, Hosford K, Francis C, Xie JM, Mugenyi P, Kataaha P, Katongole-Mbidde E, Anokbonggo WW, Guyden J, et al. Relative reactivity of the V3 loop PND of HIV-1 subtypes A, B, C, D, and F with sera from selected Ugandan localities. *Arch Virol.* 1995;140(8):1393-404.
2. Schwander S, Rüschi-Gerdes S, Mateega A, Lutalo T, Tugume S, Kityo C, Rubaramira R, Mugenyi P, Okwera A, Mugerwa R. A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis. *Tuber Lung Dis.* 1995 Jun; 76(3):210-8.
3. Tugume SB, Piwowar EM, Lutalo T, Mugenyi PN, Grant RM, Mangeni FW, Pattishall K, Katongole-Mbidde E. Hematological reference ranges among healthy Ugandans. *Clin Diagn Lab Immunol.* 1995 Mar;2(2):233-5.
4. Colebunders R, Karita E, Taelman H, Mugenyi P. Antiretroviral treatment in Africa. *AIDS.* 1997;11 Suppl B:S107-13. Review.
5. Hom D, Johnson J, Mugenyi P, Byaruhanga R, Kityo C, Loughlin A, Svilar GM, Vjecha M, Mugerwa R, Ellner J. HIV-1 Risk and Vaccine Acceptability in the Ugandan Military. *Journal of AIDS and Human Retroviruses* 1997; 15:375-80.
6. Schwander SK, Dietrich M, Mugenyi P, Kityo C, Okwera A, Johnson J, Nsubuga P, Ruesch-Gerdes S, Whalen C. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy. *East Afr Med J.* 1997 Sep;74(9):543-8.
7. Whalen CC, Johnson JL, Okwera A, Hom DL, Mugenyi P, Kityo C, Mugerwa RD, Ellner JJ. A Trial of three regimens to prevent tuberculosis in Uganda adults infected with the human immunodeficiency virus. *N Engl J Med* 1997; 337 (12):801-8.
8. Wieland U, Seelhoff A, Hofmann A, Kühn JE, Eggers HJ, Mugenyi P, Schwander S. Diversity of the vif gene of human immunodeficiency virus type 1 in Uganda. *Gen Virol.* 1997 Feb;78 (Pt 2):393-400.
9. Johnson JL, Nyole S, Okwera A, Whalen CC, Nsubuga P, Pekovic V, Huebner R, Wallis RS, Mugenyi PN, Mugerwa RD, Ellner JJ. Instability of tuberculin and Candida skin test reactivity in HIV-infected Ugandans. The Uganda-Case Western Reserve University Research Collaboration. *Am J Respir Crit Care Med.* 1998 Dec;158(6):1790-6.
10. Hirsch CS, Toossi Z, Vanham G, Johnson JL, Peters P, Okwera A, Mugerwa R, Mugenyi P, Ellner JJ. Apoptosis and T cell hyporesponsiveness in pulmonary tuberculosis. *J Infect Dis.* 1999 Apr;179(4):945-53.

Year 2000 – 2001

11. Cao H, Mani I, Vincent R, Mugerwa R, Mugenyi P, Kanki P, Ellner J, Walker BD. Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. *J Infect Dis.* 2000 Nov;182(5):1350-6. Epub 2000 Oct 9.
12. Hertoghe T, Wajja A, Ntambi L, Okwera A, Aziz MA, Hirsch C, Johnson J, Toossi Z, Mugerwa R, Mugenyi P, Colebunders R, Ellner J, Vanham G. T cell activation, apoptosis and cytokine dysregulation in the (co)pathogenesis of HIV and pulmonary tuberculosis (TB). *Clin Exp Immunol.* 2000 Dec;122(3):350-7.
13. Joloba M L; Johnson J L; Namale A; Morrissey A; Assegghai A E; Mugerwa R D; Ellner J J; Eisenach K D. Quantitative sputum bacillary load during rifampin-containing short course chemotherapy in human immunodeficiency virus-infected and non-infected adults with pulmonary tuberculosis. *The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease* 2000; 4(6):528-36.
14. Joloba M L; Whalen C C; Cave D M; Eisenach K D; Johnson J L; Okwera A; Morrissey A; Bajaksouzian S; Feagin J; Mugerwa R; Ellner J; Jacobs M R. Determination of drug susceptibility and DNA fingerprint patterns of clinical isolates of *Mycobacterium tuberculosis* from Kampala, Uganda. *East African Medical Journal* 2000;77(2):111-5.
15. Oishi K, Hayano M, Yoshimine H, Tugume SB, Kebba A, Mugerwa R, Mugenyi P, Kumatori A, Matsushima K, Nagatake T. Expression of chemokine receptors on CD4+ T cells in peripheral blood from HIV-infected individuals in Uganda. *J Interferon Cytokine Res.* 2000 Jun; 20(6):597-602.
16. Hirsch CS, Toossi Z, Johnson JL, Luzze H, Ntambi L, Peters P, McHugh M, Okwera A, Joloba M, Mugenyi P, Mugerwa RD, Terebuh P, Ellner JJ. Augmentation of apoptosis and interferon-gamma production at sites of active *Mycobacterium tuberculosis* infection in human tuberculosis. *J Infect Dis.* 2001 Mar 1;183(5):779-88. Epub 2001 Feb 8.
17. Johnson JL, Okwera A, Hom DL, Mayanja H, Mutuluza Kityo C, Nsubuga P, Nakibali JG, Loughlin AM, Yun H, Mugenyi PN, Vernon A, Mugerwa RD, Ellner JJ, Whalen CC; Uganda-Case Western Reserve University Research Collaboration. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. *AIDS.* 2001 Nov 9;15(16):2137-47.
18. Joloba M L; Johnson J L; Namale A; Morrissey A; Assegghai A E; Rüscher-Gerdes S; Mugerwa R D; Ellner J J; Eisenach K D. Quantitative bacillary response to treatment in *Mycobacterium tuberculosis* infected and *M. africanum* infected adults with pulmonary tuberculosis. *The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease* 2001;5(6):579-82.
19. Toossi Z, Johnson JL, Kanost RA, Wu M, Luzze H, Peters P, Okwera A, Joloba M, Mugenyi P, Mugerwa RD, Aung H, Ellner JJ, Hirsch CS. Increased replication of

HIV-1 at sites of Mycobacterium tuberculosis infection: potential mechanisms of viral activation. *J Acquir Immune Defic Syndr*. 2001 Sep 1;28(1):1-8.

20. Toossi Z, Mayanja-Kizza H, Hirsch CS, Edmonds KL, Spahlinger T, Hom DL, Aung H, Mugenyi P, Ellner JJ, Whalen CW. Impact of tuberculosis (TB) on HIV-1 activity in dually infected patients. *Clin Exp Immunol*. 2001 Feb; 123(2):233-8.
21. Weidle PJ, Kityo CM, Mugenyi P, Downing R, Kebba A, Pieniazek D, Respass R, Hertogs K, De Vroey V, Dehertogh P, Bloor S, Larder B, Lackritz E. Resistance to antiretroviral therapy among patients in Uganda. *J Acquir Immune Defic Syndr*. 2001 Apr 15;26(5):495-500.

Year 2002/2003

22. Kebba A, Atwine D, Mwebaze R, Kityo C, Nakityo R, Peter M. Therapeutic responses to AZT + 3TC + EFV in advanced antiretroviral naive HIV type 1-infected Ugandan patients. *AIDS Res Hum Retroviruses*. 2002 Nov 1;18(16):1181-7.
23. Mugerwa RD, Kaleebu P, Mugenyi P, Katongole-Mbidde E, Hom DL, Byaruhanga R, Salata RA, Ellner JJ; HIV-1 Vaccine Trial Group. First trial of the HIV-1 vaccine in Africa: Ugandan experience. *BMJ*. 2002 Jan 26;324(7331):226-9.
24. Mugenyi PN. HIV vaccines: the Uganda experience. *Vaccine*. 2002 May 6;20(15):1905-8. Review.
25. Nieman S, Rusch-Gerdes S, Joloba ML, Whalen CC, Guwatudde D, Ellner JJ, Eisenach K, Fomukong N, Johnson JL, Mugerwa RD, Okwera A, Schwander SK. Mycobacterium africanum subtype II is associated with two distinct genotypes and is a major cause of human tuberculosis in Kampala, Uganda. *J Clin Microbiol* 2002; 40:3398-3405.
26. Rabkin M, El-Sadr W, Katzenstein DA, Mukherjee J, Masur H, Mugenyi P, Munderi P, Darbyshire J. Antiretroviral treatment in resource-poor settings: clinical research priorities. *Lancet*. 2002 Nov 9; 360 (9344):1503-5.
27. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, Downing R, Hanson D, Ochola D, Mugenyi P, Mermin J, Samb B, Lackritz E. Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. *Lancet*. 2002 Jul 6; 360(9326):34-40.
28. Cao H, Kaleebu P, Hom D, Flores J, Agrawal D, Jones N, Serwanga J, Okello M, Walker C, Sheppard H, El-Habib R, Klein M, Mbidde E, Mugenyi P, Walker B, Ellner J, Mugerwa R; HIV Network for Prevention Trials. Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. *J Infect Dis*. 2003 Mar 15;187(6):887-95.
29. Johnson JL, Ssekasanvu E, Okwera A, Mayanja H, Hirsch CS, Nakibali J, Drzayich Jankus D, Eisenach KD, Boom WH, Ellner JJ, Mugerwa RD for the Uganda-Case

Western Reserve University Research Collaboration. Randomized trial of adjunctive interleukin-2 in adults with pulmonary tuberculosis. *Am J Respir Crit Care Med* 2003; 168:185-191.

30. Nanyunja M, Lewis RF, Makumbi I, Seruyange R, Kabwongera E, Mugenyi P, Talisuna A. Impact of mass measles campaigns among children less than 5 years old in Uganda. *J Infect Dis*. 2003 May 15;187 Suppl 1:S63-8.
31. Takahashi H, Oishi K, Yoshimine H, Kumatori A, Moji K, Watanabe K, Nalwoga H, Tugume SB, Kebba A, Mugerwa R, Mugenyi P, Nagatake T. Decreased serum opsonic activity against *Streptococcus pneumoniae* in human immunodeficiency virus-infected Ugandan adults. *Clin Infect Dis*. 2003 Dec 1;37(11):1534-40. Epub 2003 Nov 6.

Year 2004

32. Bateganya M, Colfax G, Shafer LA, Kityo C, Mugenyi P, Serwadda D, Mayanja H, Bangsberg D. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses*. 2004 Apr;20(4):355-64.
33. Gao Y, Paxinos E, Galovich J, Troyer R, Baird H, Abreha M, Kityo C, Mugenyi P, Petropoulos C, Arts EJ. Characterization of a subtype D human immunodeficiency virus type 1 isolate that was obtained from an untreated individual and that is highly resistant to nonnucleoside reverse transcriptase inhibitors. *J Virol*. 2004 May;78(10):5390-401.
34. Motomura K, Toyoda N, Oishi K, Sato H, Nagai S, Hashimoto S, Tugume SB, Enzama R, Mugewa R, Mutuluza CK, Mugyeyi P, Nagatake T, Matsushima K. Identification of a host gene subset related to disease prognosis of HIV-1 infected individuals. *Int Immunopharmacol*. 2004 Dec 20;4(14):1829-36.
35. Mugenyi P. Highly active antiretroviral therapy. *BMJ*. 2004 Nov 13;329(7475):1118-9.
36. Oyugi JH, Byakika-Tusiime J, Charlebois ED, Kityo C, Mugerwa R, Mugenyi P, Bangsberg DR. Multiple validated measures of adherence indicate high levels of adherence to generic HIV antiretroviral therapy in a resource-limited setting. *J Acquir Immune Defic Syndr*. 2004 Aug 15;36(5):1100-2.
37. Richard N, Juntilla M, Abraha A, Demers K, Paxinos E, Galovich J, Petropoulos C, Whalen CC, Kyeyune F, Atwine D, Kityo C, Mugenyi P, Arts EJ. High prevalence of antiretroviral resistance in treated Ugandans infected with non-subtype B human immunodeficiency virus type 1. *AIDS Res Hum Retroviruses*. 2004 Apr;20(4):355-64.

38. Schmid GP, Buvé A, Mugenyi P, Garnett GP, Hayes RJ, Williams BG, Calleja JG, De Cock KM, Whitworth JA, Kapiga SH, Ghys PD, Hankins C, Zaba B, Heimer R, Boerma JT. Transmission of HIV-1 infection in sub-Saharan Africa and effect of elimination of unsafe injections. *Lancet*. 2004 Feb 7;363(9407):482-8.
39. Toossi Z, Mayanja-Kizza H, Kanost A, Edmonds K, McHugh M, Hirsch C. Protective responses in tuberculosis: induction of genes for interferon-gamma and cytotoxicity by *Mycobacterium tuberculosis* and during human tuberculosis. *Scand J Immunol*. 2004 Sep;60(3):299-306.

Year 2005

40. Barugahare B, Baker C, K'Aluoch O, Donovan R, Elrefaei M, Eggena M, Jones N, Mutalya S, Kityo C, Mugenyi P, Cao H. Human immunodeficiency virus-specific responses in adult Ugandans: patterns of cross-clade recognition. *J Virol*. 2005 Apr;79(7):4132-9.
41. Bateganya M, Colfax G, Shafer LA, Kityo C, Mugenyi P, Serwadda D, Mayanja H, Bangsberg D. Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. *AIDS Patient Care STDS*. 2005 Nov;19(11):760-8.
42. Byakika-Tusiime J, Oyugi JH, Tumwikirize WA, Katabira ET, Mugenyi PN, Bangsberg DR. Adherence to HIV antiretroviral therapy in HIV+ Ugandan patients purchasing therapy. *Int J STD AIDS*. 2005 Jan;16(1):38-41.
43. Eggena MP, Barugahare B, Jones N, Okello M, Mutalya S, Kityo C, Mugenyi P, Cao H. Depletion of regulatory T cells in HIV infection is associated with immune activation. *J Immunol*. 2005 Apr 1;174(7):4407-14.
44. Eggena MP, Barugahare B, Okello M, Mutyala S, Jones N, Ma Y, Kityo C, Mugenyi P, Cao H. T cell activation in HIV-seropositive Ugandans: differential associations with viral load, CD4+ T cell depletion, and coinfection. *J Infect Dis*. 2005 Mar 1;191(5):694-701.
45. Hirsch CS, Johnson JL, Okwera A, Kanost RA, Wu M, Peters P, Muhumuza M, Mayanja-Kizza H, Mugerwa RD, Mugenyi P, Ellner JJ, Toossi Z. Mechanisms of apoptosis of T-cells in human tuberculosis. *J Clin Immunol*. 2005 Jul;25(4):353-64.
46. Kizza HM, Rodriguez B, Quinones-Mateu M, Mirza M, Aung H, Yen-Lieberman B, Starkey C, Horter L, Peters P, Baseke J, Johnson JL, Toossi Z. Persistent replication of human immunodeficiency virus type 1 despite treatment of pulmonary tuberculosis in dually infected subjects. *Clin Diagn Lab Immunol*. 2005 Nov;12(11):1298-304.
47. McElroy MD, Elrefaei M, Jones N, Ssali F, Mugenyi P, Barugahare B, Cao H. Coinfection with *Schistosoma mansoni* is associated with decreased HIV-specific cytotoxicity and increased IL-10 production. *J Immunol*. 2005 Apr 15;174(8):5119-23.

48. Namayanja GK, Nankya JM, Byamugisha JK, Ssali FN, Kityo CM, Rwambuya SD, Mugerwa RD, Mmiro FA, Morrison CS, Salata RA. Stevens - Johnson syndrome due to nevirapine. *Afr Health Sci.* 2005 Dec;5(4):338-40.
49. Toossi Z, Mayanja-Kizza H, Baseke J, Peters P, Wu M, Abraha A, Aung H, Okwera A, Hirsch C, Arts E. Inhibition of human immunodeficiency virus-1 (HIV-1) by beta-chemokine analogues in mononuclear cells from HIV-1-infected patients with active tuberculosis. *Clin Exp Immunol.* 2005 Nov;142(2):327-32.

Year 2006

50. Blossom DB, Namayanja-Kaye G, Nankya-Mutyoba J, Mukasa JB, Bakka H, Rwambuya S, Windau A, Bajaksouzian S, Walker CJ, Joloba ML, Kityo C, Mugenyi P, Whalen CC, Jacobs MR, Salata RA. Oropharyngeal colonization by *Streptococcus pneumoniae* among HIV-infected adults in Uganda: assessing prevalence and antimicrobial susceptibility. *Int J Infect Dis.* 2006 Nov;10(6):458-64.
51. DART Virology Group and Trial Team. Virological response to a triple nucleoside/nucleotide analogue regimen over 48 weeks in HIV-1-infected adults in Africa. *AIDS.* 2006 Jun 26;20(10):1391-9.
52. Edward C Jones-López , Alphonse Okwera , Harriet Mayanja-Kizza , Jerrold J Ellner , Roy D Mugerwa , Christopher C Whalen. Delayed-type hypersensitivity skin test reactivity and survival in hiv-infected patients in uganda: should anergy be a criterion to start antiretroviral therapy in low-income countries? *Am J Trop Med Hyg.* 2006; 74 (1):154-161.
53. Eggena MP, Hopkins H, Barugahare B, Okello M, Ssali F, Mugenyi P, Rosenthal PJ, Cao H, Dorsey G. CD4 T cell activation as a predictor for treatment failure in Ugandans with *Plasmodium falciparum* malaria. *Am J Trop Med Hyg.* 2006 Jan;74(1):41-3.
54. Elrefaei M, Barugahare B, Ssali F, Mugenyi P, Cao H. HIV-specific IL-10-positive CD8+ T cells are increased in advanced disease and are associated with decreased HIV-specific cytotoxicity. *J Immunol.* 2006 Jan 15; 176(2):1274-80.
55. Hyun J Lim , Alphonse Okwera , Harriet Mayanja-Kizza , Jerrold J Ellner , Roy D Mugerwa , Christopher C Whalen. Effect of Tuberculosis Preventive Therapy on HIV Disease Progression and Survival in HIV-Infected Adults. *HIV Clin Trials.* 2006; 7 (4):172-83.

56. Jones N, Eggena M, Baker C, Nghania F, Baliruno D, Mugenyi P, Ssali F, Barugahare B, Cao H. Presence of distinct subsets of cytolytic CD8+ T cells in chronic HIV infection. *AIDS Res Hum Retroviruses*. 2006 Oct;22(10):1007-13.

57. Muhumuza J; Asiimwe B B; Kayes S; Mugenyi R; Whalen C; Mugerwa R D; Boom H; Eisenach K D; Joloba M L. Introduction of an in-house PCR for routine identification of *M. tuberculosis* in a low-income country. *The international journal of tuberculosis and lung disease: the official journal of the International Union against Tuberculosis and Lung Disease* 2006; 10(11):1262-7.

58. Ssali F, Stohr W, Munderi P, Reid A, Walker AS, Gibb DM, Mugenyi P, Kityo C, Grosskurth H, Hakim J, Byakwaga H, Katabira E, Darbyshire JH, Gilks CF; DART Trial Team. Prevalence, incidence and predictors of severe anaemia with zidovudine-containing regimens in African adults with HIV infection within the DART trial. *Antivir Ther*. 2006;11(6):741-9.

59. Whalen CC, Chiunda A, Zalwango S, Nshuti L, Jones-Lopez E, Okwera A, Hirsch C, Peters P, Boom WH, Mugerwa RD. Immune correlates of acute *Mycobacterium tuberculosis* infection in household contacts in Kampala, Uganda. *Am J Trop Med Hyg*. 2006 Jul;75(1):55-61.

60. Mugenyi P, Kityo Mutuluza C. et al. Scaling up Antiretroviral Therapy: Experience of the Joint Clinical Research Centre in Uganda 2006, *Acta Academica* Dec 2006

Year 2007

61. Blossom DB, Cordeiro SM, Bajaksouzian S, Joloba ML, Kityo C, Whalen CC, Salata RA, Jacobs MR. Characterization of penicillin intermediate serotypes of *Streptococcus pneumoniae* carried by human immunodeficiency virus-infected adults and healthy children in Uganda. *Microb Drug Resist*. 2007 Spring;13(1):21-8.

62. Karita E, Price M, Hunter E, Chomba E, Allen S, Fei L, Kamali A, Sanders EJ, Anzala O, Katende M, Ketter N; the IAVI Collaborative Seroprevalence and Incidence Study Team. Investigating the utility of the HIV-1 BED capture enzyme immunoassay using cross-sectional and longitudinal seroconverter specimens from Africa. *AIDS*. 2007 Feb 19;21(4):403-408.

63. Kiguba R, Byakika-Tusiime J, Karamagi C, Ssali F, Mugenyi P, Katabira E. Discontinuation and modification of highly active antiretroviral therapy in HIV-infected Ugandans: prevalence and associated factors. *J Acquir Immune Defic Syndr*. 2007 Jun 1;45(2):218-23.
64. Kikaire B, Khoo S, Walker AS, Ssali F, Munderi P, Namale L, Reid A, Gibb DM, Mugenyi P, Grosskurth H; DART Trial Team. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. *AIDS*. 2007 Mar 30;21(6):733-7.
65. Mabumba ED, Mugenyi P, Batwala V, Mulogo EM, Mirembe J, Khan FA, Liljestrand J. Widow inheritance and HIV/AIDS in rural Uganda. *Trop Doct*. 2007 Oct; 37(4):229-31.
66. Musiime V, Ssali F, Kizito H, Kityo C, Mugenyi P. Need for review of prevention of mother-to-child transmission practice especially in discordant couples: a case of mother-to-child transmission of HIV during breast feeding by a mother who tested HIV negative antenatally. *AIDS*. 2007 Jul 31;21(12):1658-9.
67. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, Kityo C, Mugenyi P, Quinn TC, Bangsberg DR. Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. *AIDS*. 2007 May 11; 21(8):965-71.
68. Penzak SR, Kabuye G, Mugenyi P, Mbamanya F, Natarajan V, Alfaro RM, Kityo C, Formentini E, Masur H. Cytochrome P450 2B6 (CYP2B6) G516T influences nevirapine plasma concentrations in HIV-infected patients in Uganda. *HIV Med*. 2007 Mar; 8(2):86-91.
69. Sow PS, Otieno LF, Bissagnene E, Kityo C, Bennink R, Clevenbergh P, Wit FW, Waalberg E, Rinke de Wit TF, Lange JM; on behalf of the Cohort Program to Evaluate Access to Antiretroviral Therapy and Education Project Team. Implementation of an Antiretroviral Access Program for HIV-1-Infected Individuals in Resource-Limited Settings: Clinical Results From 4 African Countries. *J Acquir Immune Defic Syndr*. 2007 Mar 1;44(3):262-7.
70. Traore, H., S. Ogwang, K. Mallard, M. L. Joloba, F. Mumbowa, K. Narayan, S. Kayes, E. C. Jones-Lopez, P. G. Smith, J. J. Ellner, R. D. Mugerwa, K. D. Eisenach,

and R. McNerney. "Low-Cost Rapid Detection of Rifampicin Resistant Tuberculosis Using Bacteriophage in Kampala, Uganda." *Ann Clin Microbiol Antimicrob* 6, (2007): 1.

71. Zahra Toossi , Harriet Mayanja-Kizza , Stephen D Lawn , Christina S Hirsch , L Davis Lupo , Salvatore T Butera. Dynamic Variation in the Cellular Origin of HIV Type 1 during Treatment of Tuberculosis in Dually Infected Subjects. *AIDS Res Hum Retroviruses*. 2007; 23 (1):93-100.

Year 2008

72. Chen M, Ssali F, Mulungi M, Awio P, Yoshimine H, Kuroki R, Furumoto A, Tanimura S, Kityo C, Nagatake T, Mugenyi P, Oishi K. Induction of opsonophagocytic killing activity with pneumococcal conjugate vaccine in human immunodeficiency virus-infected Ugandan adults. *Vaccine*. 2008 Jul 17.
73. Dickinson L, Boffito M, Back DJ, Khoo SH, Pozniak AL, Mugenyi P, Merry C, Autar RS, Burger DM, Aarons LJ. Population pharmacokinetics of ritonavir-boosted saquinavir regimens in HIV-infected individuals. *J Antimicrob Chemother*. 2008 Dec;62(6):1344-55. Epub 2008 Sep 29.
74. Goletti D, Carrara S, Mayanja-Kizza H, Baseke J, Mugerwa MA, Girardi E, Toossi Z. Response to M. Tuberculosis selected RD1 peptides in Ugandan HIV with smear positive pulmonary tuberculosis. *BMC Infect Dis*. 2008 Jan 28;8:11.
75. Lewinsohn DA, Zalwango S, Stein CM, Mayanja-Kizza H, Okwera A, Boom WH, Mugerwa RD, Whalen CC. Whole blood interferon-gamma responses to mycobacterium tuberculosis antigens in young household contacts of persons with tuberculosis in Uganda. *PLoS One*. 2008;3(10):e3407.
76. Musingo SK, Walker AS, Reid A, Munderi P, Gibb DM, Ssali F, Levin J, Katabira E, Gilks C, Todd J; DART Trial Team. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. *J Acquir Immune Defic Syndr*. 2008 Aug 1;48(4):468-75.

77. Reid A, Stöhr W, Walker AS, Williams IG, Kityo C, Hughes P, Kambugu A, Gilks CF, Mugenyi P, Munderi P, Hakim J, Gibb DM; Development of Antiretroviral Therapy Trial. Severe renal dysfunction and risk factors associated with renal impairment in HIV-infected adults in Africa initiating antiretroviral therapy. *Clin Infect Dis*. 2008 Apr 15;46(8):1271-81.
78. Suligoi B, Buttò S, Galli C, Bernasconi D, Salata RA, Tavošchi L, Chiappi M, Mugenyi P, Pimpinelli F, Kityo C, Regine V, Rezza G. Detection of recent HIV infections in African individuals infected by HIV-1 non-B subtypes using HIV antibody avidity. *J Clin Virol*. 2008 Apr;41(4):288-92. Epub 2008 Jan 8.
79. Temple, B., I. Ayakaka, S. Ogwang, H. Nabanjja, S. Kayes, S. Nakubulwa, W. Worodria, J. Levin, M. Joloba, A. Okwera, K. D. Eisenach, R. McNerney, A. M. Elliott, P. G. Smith, R. D. Mugerwa, J. J. Ellner, and E. C. Jones-Lopez. "Rate and Amplification of Drug Resistance among Previously-Treated Patients with Tuberculosis in Kampala, Uganda." *Clin Infect Dis* 47, no. 9 (2008): 1126-34.
80. The DART Trial Team; Twenty-four-week safety and tolerability of nevirapine vs. abacavir in combination with zidovudine/lamivudine as first-line antiretroviral therapy: a randomized double-blind trial (NORA). *Tropical Medicine and International Health*, Vol 13, Number 1, pp 6-16, Jan 2008.
81. Troyer RM, Lalonde MS, Fraundorf E, Demers KR, Kyeyune F, Mugenyi P, Syed A, Whalen CC, Bajunirwe F, Arts EJ. A radiolabeled oligonucleotide ligation assay demonstrates the high frequency of nevirapine resistance mutations in HIV type 1 quasispecies of NVP-treated and untreated mother-infant pairs from Uganda. *AIDS Res Hum Retroviruses*. 2008 Feb;24(2):235-50.

Year 2009

82. Musiime V, Kalyesubula I, Kaddu-Mulindwa DH, Byarugaba J. Enteric bacterial pathogens in HIV infected children with acute diarrhea in Mulago referral and teaching hospital, Kampala, Uganda. *J Int Assoc Physicians AIDS Care (Chic Ill)*. 2009 May-Jun;8(3):185-90. Epub 2009 April 2008.
83. Canaday DH, Wu M, Lu S, Aung H, Peters P, Baseke J, Mackay W, Mayanja-Kizza H, Toossi Z, 2009. Induction of HIV type 1 expression correlates with T cell responsiveness to mycobacteria in patients coinfecting with HIV type 1 and *Mycobacterium tuberculosis*. *AIDS Res Hum Retroviruses* 25(2):213-6.

84. Kigozi BK, Sumba S, Mudyope P, Namuddu B, Kalyango J, Karamagi C, Odere M, Katabira E, Mugenyi P, Ssali F. The effect of AIDS defining conditions on immunological recovery among patients initiating antiretroviral therapy at Joint Clinical Research Centre, Uganda. *AIDS Res Ther.* 2009 Jul 24;6:17.

85. Mugenyi P. Flat-line funding for PEPFAR: a recipe for chaos. *Lancet.* 2009 Jul 25; 374(9686):292.

86. Musiime V, Ssali F, Kayiwa J, Namala W, Kizito H, Kityo C, Mugenyi P. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine. *AIDS Res Hum Retroviruses.* 2009 Oct; 25(10):989-96. Epub 2009 Sep 24.

87. Ntanda H, Olupot-Olupot P, Mugenyi P, Kityo C, Lowes R, Cooper C, Lima V, Mills E: Orphanhood predicts delayed access to care in Ugandan children. *Pediatr Infect Dis J* 2009, 28(2):153-155.

88. Ogwang Sam; Asiimwe Benon B; Traore Hamidou; Mumbowa Francis; Okwera Alphonse; Eisenach Kathleen D; Kayes Susan; Jones-López Edward C; McNerney Ruth; Worodria William; Ayakaka Irene; Mugerwa Roy D; Smith Peter G; Ellner Jerrold; Joloba Moses L Comparison of rapid tests for detection of rifampicin-resistant *Mycobacterium tuberculosis* in Kampala, Uganda. *BMC infectious diseases* 2009; 9():139. [Link](#)

89. Rabkin M, El-Sadr WM, De Cock KM; Bellagio HIV/Health Systems Working Group1. The impact of HIV scale-up on health systems: A priority research agenda. *J Acquir Immune Defic Syndr.* 2009 Nov;52 Suppl 1:S6-11. [Link](#)

90. Reynolds SJ, Kityo C, Mbamanya F, Dewar R, Ssali F, Quinn TC, Mugenyi P, Dybul M. Evolution of drug resistance after virological failure of a first-line highly active antiretroviral therapy regimen in Uganda. *Antivir Ther.* 2009; 14(2):293-7. [Link](#)

91. Wagner G, Ryan G, Huynh A, Kityo C, Mugenyi P: A qualitative analysis of the economic impact of HIV and antiretroviral therapy on individuals and households in Uganda. *AIDS Patient Care STDS* 2009, 23(9):793-798. [Link](#)

92. Mills EJ, Ford N, Mugenyi P. Expanding HIV care in Africa: making men matter. *Lancet*. 2009 Jul 25; 374(9686):275-6.
93. Johnson JL, Hadad DJ, Dietze R, Noia Maciel EL, Sewali B, Gitta P, Okwera A, Mugerwa RD, Alcaneses MR, Quelapio MI, Tupasi TE, Horter L, Debanne SM, Eisenach KD, Boom WH. *Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion*. *Am J Respir Crit Care Med*. 2009 Sep 15;180(6):558-63. Epub 2009 Jun 19
94. Sendagire H, Easterbrook PJ, Nankya I, Arts E, Thomas D, Reynolds S. The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART J. *AIDS Rev*. 2009 Apr-Jun;11(2):59-70.

Year 2010

95. DART Trial Team. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. *Lancet* 2010; 375:123-31.
96. Kityo C, Walker AS, Dickinson L, Lutwama F, Kayiwa J, Ssali F, Nalumenya R, Tumukunde D, Munderi P, Reid A, Gilks CF, Gibb DM, Khoo S; on behalf of the DART trial team. Pharmacokinetics of Lopinavir/Ritonavir with and without Non-Nucleoside Reverse Transcriptase Inhibitors in Uganda HIV infected adults. *Antimicrob Agents Chemother*. 2010 Apr 26.
97. Mahan CS, Walusimbi M, Johnson DF, Lancioni C, Charlebois E, Baseke J, Chervenak KA, Mugerwa RD, Havlir DV, Mayanja-Kizza H, Whalen CC, Boom WH; Uganda-Case Western Research Collaboration. Tuberculosis treatment in HIV infected Ugandans with CD4 counts >350 cells/mm reduces immune activation with no effect on HIV load or CD4 count. *PLoS One*. 2010 Feb 22;5(2):e9138.

98. Leidl L, Mayanja-Kizza H, Sotgiu G, Baseke J, Ernst M, Hirsch C, Goletti D, Toossi Z, Lange C. [Relationship of immunodiagnostic assays for tuberculosis and numbers of circulating CD4+ T-cells in HIV infection.](#) Eur Respir J. 2010 Mar;35(3):619-26. doi: 10.1183/09031936.00045509. Epub 2009 Jul 16.
99. McCormick AL, Goodall RL, Joyce A, Ndemi N, Chirara M, Katundu P, Walker S, Yirrell D, Gilks CF, Pillay D; DART Virology Group and Trial Team. Lack of minority K65R-resistant viral populations detected after repeated treatment interruptions of tenofovir/zidovudine and lamivudine in a resource-limited setting. J Acquir Immune Defic Syndr. 2010 Jun;54(2):215-6.
100. Munderi P, Walker AS, Kityo C, Babiker AG, Ssali F, Reid A, Darbyshire JH, Grosskurth H, Mugenyi P, Gibb DM, Gilks CF; DART/NORA trial teams. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts. HIV Med. 2010 May;11(5):334-44. Epub 2010 Feb 3.
101. Ndemi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V et al: Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir. J Infect Dis 2010, 201(1):106-113.
102. Orikiiriza J, Bakeera-Kitaka S, Boulware D R, Musiime V, Mworzi E A, Mugenyi P. The clinical pattern, prevalence and factors associated with Immune reconstitution inflammatory syndrome in Ugandan children. AIDS. 2010 July 7.
103. Reynolds SJ, Kityo C, Hallahan CW, Kabuye G, Atwiine D, Mbamanya F, Ssali F, Dewar R, Daucher M, Davey RT, Jr. et al: A randomized, controlled, trial of short cycle intermittent compared to continuous antiretroviral therapy for the treatment of HIV infection in Uganda. PLoS One 2010, 5(4):e10307.
104. Wagner GJ, Holloway I, Ghosh-Dastidar B, Ryan G, Kityo C, Mugenyi P: Factors Associated with Condom Use Among HIV Clients in Stable Relationships with Partners at Varying Risk for HIV in Uganda. AIDS Behav. 2010, 2.
105. Li L, Mahan CS, Palaci M, Horter L, Loeffelholz L, Johnson JL, Dietze R, Debanne SM, Joloba ML, Okwera A, Boom WH, Eisenach KD. Sputum

Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to anti-tuberculosis therapy. *J Clin Microbiol*, 2010; 48:46-51. PMID: PMC2812283.

106. Kateete DP, Okee M, Katabazi FA, Okeng A, Asiimwe J, Boom HW, Eisenach KD, Joloba ML. Rhomboid homologs in mycobacteria: insights from phylogeny and genomic analysis. *BMC Microbiol*. 2010; 10:272. PMID: PMC2989971.
107. Musiime V, Kendal L, Bakeera-Kitaka S, Snowden B, Thomason M, Musoke P, Adkison K, Odongo F, Burger D, Mugenyi P, Kekitiinwa A, Gibb D, Walker S; ARROW trial team. Pharmacokinetics and acceptability of once versus twice daily lamivudine and abacavir in HIV-1 infected Ugandan children in the ARROW trial. *Antivir Ther*. 2010; 15(8):1115-24.

Year 2011

108. Haberer, J. E.; Cook, A.; Walker, A. S.; Ngambi, M.; Ferrier, A.; Mulenga, V.; Kityo, C.; Thomason, M.; Kabamba, D.; Chintu, C.; Gibb, D. M.; Bangsberg, D. R., Excellent adherence to antiretrovirals in HIV+ Zambian children is compromised by disrupted routine, HIV nondisclosure, and paradoxical income effects. *PLoS One* 2011, 6, (4), e18505.
109. Hamers, R. L.; Oyomopito, R.; Kityo, C.; Phanuphak, P.; Siwale, M.; Sungkanuparph, S.; Conradie, F.; Kumarasamy, N.; Botes, M. E.; Sirisanthana, T.; Abdallah, S.; Li, P. C.; Ngorima, N.; Kantipong, P.; Osibogun, A.; Lee, C. K.; Stevens, W. S.; Kamarulzaman, A.; Derdelinckx, I.; Chen, Y. M.; Schuurman, R.; Vugt, M. V.; Rinke de Wit, T. F., Cohort Profile: The PharmAccess African (PASER-M) and the TREAT Asia (TASER-M) Monitoring Studies to Evaluate Resistance-- HIV drug resistance in sub-Saharan Africa and the Asia-Pacific. *Int J Epidemiol* 2011.
110. Kityo, C.; Bousheri, S.; Akao, J.; Ssali, F.; Byaruhanga, R.; Ssewanyana, I.; Muloma, P.; Myalo, S.; Magala, R.; Lu, Y.; Mugenyi, P.; Cao, H., Therapeutic immunization in HIV infected Ugandans receiving stable antiretroviral treatment: a Phase I safety study. *Vaccine* 2011, 29, (8), 1617-23.
111. McCormick, A. L.; Parry, C. M.; Crombe, A.; Goodall, R. L.; Gupta, R. K.; Kaleebu, P.; Kityo, C.; Chirara, M.; Towers, G. J.; Pillay, D., Impact of the N348I mutation in HIV-1 reverse transcriptase on nonnucleoside reverse transcriptase inhibitor resistance in non-subtype B HIV-1. *Antimicrob Agents Chemother* 2011, 55, (4), 1806-9.

112. Munderi, P.; Snowden, W. B.; Walker, A. S.; Kityo, C.; Mosteller, M.; Kabuye, G.; Thoofer, N. K.; Ssali, F.; Gilks, C. F.; Hughes, A. R., Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. *Trop Med Int Health* 2011, 16, (2), 200-4.
113. Natukunda, E.; Musiime, V.; Ssali, F.; Kizito, H.; Kityo, C.; Mugenyi, P., A Case of Cryptococcal Lymphadenitis in an HIV-Infected Child. *AIDS Res Hum Retroviruses* 2011, 27, (4), 373-6.
114. Tivoschi L, Bernasconi D, Chiappi M, Suligo B, Galli C, Regine V, Kityo C, Buttò S. Performance of V3-based HIV-1 sero subtyping in HIV endemic areas. *Ann Ist Super Sanita*. 2011;47(4):424-8.
115. Bark CM, Thiel BA, Johnson JL. Pretreatment time to detection of Mycobacterium tuberculosis in liquid culture is associated with relapse after therapy. [J Clin Microbiol](#). 2012 Feb; 50(2):538. Epub 2011 Nov 23
116. El-Sadr WM, Gonsalves G, Mugenyi P. No need for apologies. *J Acquir Immune Defic Syndr*. 2011 Aug;57 Suppl 2:S68-71.
117. Hamers RL, Wallis CL, Kityo C, Siwale M, Mandaliya K, Conradie F, Botes ME, Wellington M, Osibogun A, Sigaloff KC, Nankya I, Schuurman R, Wit FW, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study. *Lancet Infect Dis*. 2011 Oct;11(10):750-9.
118. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. *J Acquir Immune Defic Syndr*. 2011 Sep 1;58(1):23-31.
119. Baveewo S, Ssali F, Karamagi C, Kalyango JN, Hahn JA, Ekoru K, Mugenyi P, Katabira E. Validation of World Health Organisation HIV/AIDS clinical staging in predicting initiation of antiretroviral therapy and clinical predictors of low CD4 cell count in Uganda. *PLoS One*. 2011 May 12;6(5):e19089.
120. Wagner GJ, Holloway I, Ghosh-Dastidar B, Kityo C, Mugenyi P. Understanding the influence of depression on self-efficacy, work status and condom use among HIV clients in Uganda. *J Psychosom Res*. 2011 May;70(5):440-8.
121. Nahiry-Ntege P, Musiime V, Naidoo B, Bakeera-Kitaka S, Nathoo K, Munderi P, Mugenyi P, Kekitiinwa A, Bwakura-Dangarembizi MF, Crawley J; ARROW Trial Team. Low incidence of abacavir hypersensitivity reaction among

African children initiating antiretroviral therapy. *Pediatr Infect Dis J*. 2011 Jun;30(6):535-7.

122. [Nanteza MW](#), [Mayanja-Kizza H](#), [Charlebois E](#), [Srikantiah P](#), [Lin R](#), [Mupere E](#), [Mugenyi P](#), [Boom WH](#), [Mugerwa RD](#), [Havlin DV](#), [Whalen CC](#). A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4⁺ T-cell counts of ≥ 350 cells/ μ L. *J Infect Dis*. 2011 Sep 15;204(6):884-92
123. Bark CM, Dietze R, Okwera A, Quelapio MI, Thiel BA, Johnson JL. Clinical symptoms and microbiological outcomes in tuberculosis treatment trials. *Tuberculosis (Edinb)*. 2011 Nov;91(6):601-4. Epub 2011 Aug 2
124. Bark CM, Okwera A, Joloba ML, Thiel BA, Nakibali JG, Debanne SM, Boom WH, Eisenach KD, Johnson JL. Tuberculosis (Edinb). Pre-treatment time to detection of *Mycobacterium tuberculosis* as an alternative to quantitative cultures. 2011; 91:257-259.
125. Whalen CC, Zalwango S, Chiunda A, Malone LL, Eisenach K, Joloba M, Boom WH, Mugerwa RD. Secondary attack rate of tuberculosis in urban households in Kampala, Uganda. *Plos One*, 2011; 6:E16137. PMID: PMC3038854.
126. Morrison CS, Chen PL, Nankya I, Rinaldi A, Van Der Pol B, Ma YR, Chipato T, Mugerwa R, Dunbar M, Arts E, Salata RA. Hormonal contraceptive use and HIV disease progression among women in Uganda and Zimbabwe. *J Acquir Immune Defic Syndr*. 2011 Jun 1;57(2):157-64.
127. [Toossi Z](#), [Wu M](#), [Hirsch CS](#), [Mayanja-Kizza H](#), [Baseke J](#), [Aung H](#), [Canaday DH](#), [Fujinaga K](#). Activation of P-TEFb at Sites of Dual HIV/TB Infection, and Inhibition of MTB-Induced HIV Transcriptional Activation by the Inhibitor of CDK9, Indirubin-3'-Monoxime. *AIDS Res Hum Retroviruses*. 2011 PMID: 21453127
128. Toossi Z, Hirsch CS, Wu M, Mayanja-Kizza H, Baseke J, Thiel B. Distinct cytokine and regulatory T cell profile at pleural sites of dual HIV/tuberculosis infection compared to that in the systemic circulation. *Clin Exp Immunol*. 2011.163(3):333-8.
129. Lancioni C, Nyendak M, Kiguli S, Zalwango S, Mori T, Mayanja-Kizza H, Balyejusa S, Null M, Baseke J, Mulindwa D, Byrd L, Swarbrick G, Scott C, Johnson DF, Malone L, Mudido-Musoke P, Boom WH, Lewinsohn DM, Lewinsohn DA. CD8⁺ T cells Provide an Immunologic Signature of Tuberculosis in Young Children. *Am J Respir Crit Care Med*. 2011 PMID: 22071329

130. Lancioni CL, Mahan CS, Johnson DF, Walusimbi M, Chervenak KA, Nalukwago S, Charlebois E, Havlir D, Mayanja-Kizza H, Whalen CC, Boom WH. Effects of antiretroviral therapy on immune function of HIV-infected adults with pulmonary tuberculosis and CD4+ >350 cells/mm³. *J Infect Dis.* 2011 203(7):992-1001.
131. Prendergast A, Bwakura-Dangarembizi M, Cook A, Bakeera-Kitaka S, Natukunda E, Nahirya P, Nathoo K, Karungi C, Lutaakome J, Kekitiinwa A, Gibb DM. Acute kwashiorkor in HIV-infected African children starting antiretroviral therapy in the ARROW trial. *AIDS* 2011 Apr 24;25(7):951-6
132. Fillekes Q, Natukunda E, Balungi J, Kendall L, Bwakura-Dangarembizi M, Keishanyu R, Ferrier A, Lutakome J, Gibb DM, Burger DM, Walker AS on behalf of the ARROW trial team. Paediatric under-dosing of Efavirenz: a pharmacokinetic study in Uganda. *Journal of Acquired Immune Deficiency Syndromes* 2011 Dec 1;58(4):392-8.
133. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS on behalf of the ARROW trial team. Pharmacokinetics of oral solution versus tablet formulation varies with antiretroviral drug in the target population of HIV-1 infected children. *Clinical Pharmacology and Therapeutics* 2011 Dec 21;10.1038/clpt.2011.225
134. Stöhr W, Reid A, Walker AS, Ssali F, Munderi P, Mambule I, Kityo C, Grosskurth H, Gilks CF, Gibb DM, Hakim J; DART Trial Team. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. *Antivir Ther.* 2011;16(7):1011-20.

Year 2012

135. Hamers RL, Sigaloff KC, Kityo C, Mugenyi P, de Wit TF. Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa. *Curr Opin HIV AIDS.* 2013 Jan;8(1):19-26.
136. Wagner G, Linnemayr S, Kityo C, Mugenyi P. Factors associated with intention to conceive and its communication to providers among HIV clients in Uganda. *Matern Child Health J.* 2012 Feb;16(2):510-8.

137. Walker AS, Prendergast AJ, Mugenyi P, Munderi P, Hakim J, Kekitiinwa A, Katabira E, Gilks CF, Kityo C, Nahirya-Ntege P, Nathoo K, Gibb DM; for the DART and ARROW trial teams. Mortality in the Year Following Antiretroviral Therapy Initiation in HIV-Infected Adults and Children in Uganda and Zimbabwe. *Clin Infect Dis.* 2012 Dec;55(12):1707-1718.
138. El-Sadr WM, Holmes CB, Mugenyi P, Thirumurthy H, Ellerbrock T, Ferris R, Sanne I, Asiimwe A, Hirschall G, Nkambule RN, Stabinski L, Affrunti M, Teasdale C, Zulu I, Whiteside A. Scale-up of HIV treatment through PEPFAR: a historic public health achievement. *J Acquir Immune Defic Syndr.* 2012 Aug 15;60 Suppl 3:S96-104.
139. Palar K, Wagner G, Ghosh-Dastidar B, Mugenyi P. Role of antiretroviral therapy in improving food security among patients initiating HIV treatment and care. *AIDS.* 2012 Nov 28;26(18):2375-81..
140. Wagner GJ, Ghosh-Dastidar B, Garnett J, Kityo C, Mugenyi P. Impact of HIV Antiretroviral Therapy on Depression and Mental Health Among Clients With HIV in Uganda. *Psychosom Med.* 2012 Nov;74(9):883-90.
141. Wiens MO, MacLeod S, Musiime V, Ssenyonga M, Kizza R, Bakeera-Kitaka S, Odoi-Adome R, Ssali F. Adherence to Antiretroviral therapy in HIV-positive adolescents in Uganda assessed by multiple methods: a prospective cohort study. *Paediatr Drugs.* 2012 Oct 1;14(5):331-5.
142. Lockman S, Hughes M, Sawe F, Zheng Y, McIntyre J, Chipato T, Asmelash A, Rassool M, Kimaiyo S, Shaffer D, Hosseinipour M, Mohapi L, Ssali F, Chibowa M, Amod F, Halvas E, Hogg E, Alston-Smith B, Smith L, Schooley R, Mellors J, Currier J; OCTANE (Optimal Combination Therapy After Nevirapine Exposure) ACTG A5208/OCTANE Study Team. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial. *PLoS Med.* 2012;9(6):e1001236.
143. Hamers RL, Kityo C, Lange JM, de Wit TF, Mugenyi P. Global threat from drug resistant HIV in sub-Saharan Africa. *BMJ.* 2012 Jun 18;344:e4159.
144. Kenny J, Musiime V, Judd A, Gibb D. Recent advances in pharmacovigilance of antiretroviral therapy in HIV-infected and exposed children. *Curr Opin HIV AIDS.* 2012 Jul;7(4):305-16.
145. Sigaloff KC, Hamers RL, Menke J, Labib M, Siwale M, Ive P, Botes ME, Kityo C, Mandaliya K, Wellington M, Osibogun A, Geskus RB, Stevens WS, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance. Early warning indicators for population-based monitoring of HIV drug resistance in 6 African countries. *Clin Infect Dis.* 2012 May;54 Suppl 4:S294-9.

146. Hamers RL, Straatsma E, Kityo C, Wallis CL, Stevens WS, Sigaloff KC, Siwale M, Conradie F, Botes ME, Mandaliya K, Wellington M, Osibogun A, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance. Building capacity for the assessment of HIV drug resistance: experiences from the PharmAccess African Studies to Evaluate Resistance network. *Clin Infect Dis*. 2012 May;54 Suppl 4:S261-5.
147. Musiime V, Kayiwa J, Kiconco M, Tamale W, Alima H, Mugerwa H, Abwola M, Apilli E, Ahimbisibwe F, Kizito H, Abongomera G, Namusoke A, Makabayi A, Kiweewa F, Ssali F, Kityo C, Colebunders R, Mugenyi P. Response to Antiretroviral Therapy of HIV Type 1-Infected Children in Urban and Rural Settings of Uganda. *AIDS Res Hum Retroviruses*. 2012 Dec;28(12):1647-57.
148. Medina Lara A, Kigozi J, Amurwon J, Muchabaiwa L, Nyanzi Wakaholi B, Mujica Mota RE, Walker AS, Kasirye R, Ssali F, Reid A, Grosskurth H, Babiker AG, Kityo C, Katabira E, Munderi P, Mugenyi P, Hakim J, Darbyshire J, Gibb DM, Gilks CF; DART Trial Team. Cost effectiveness analysis of clinically driven versus routine laboratory monitoring of antiretroviral therapy in Uganda and Zimbabwe. *PLoS One*. 2012;7(4):e33672.
149. Hamers RL, Sigaloff KC, Wensing AM, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Stevens WS, Rinke de Wit TF, Schuurman R; PharmAccess African Studies to Evaluate Resistance (PASER). Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. *Clin Infect Dis*. 2012 Jun;54(11):1660-9.
150. Lamorde M, Byakika-Kibwika P, Tamale WS, Kiweewa F, Ryan M, Amara A, Tjia J, Back D, Khoo S, Boffito M, Kityo C, Merry C. Effect of Food on the Steady-State Pharmacokinetics of Tenofovir and Emtricitabine plus Efavirenz in Ugandan Adults. *AIDS Res Treat*. 2012;2012:105980.
151. Sigaloff KC, Hamers RL, Wallis CL, Kityo C, Siwale M, Ive P, Botes ME, Mandaliya K, Wellington M, Osibogun A, Stevens WS, van Vugt M, Rinke de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER). Second-line antiretroviral treatment successfully resuppresses drug-resistant HIV-1 after first-line failure: prospective cohort in Sub-Saharan Africa. *J Infect Dis*. 2012 Jun;205(11):1739-44.
152. Boender TS, Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Hamers RL, Nakatudde LK, Khauda E, Mukuye A, Ditai J, Geelen SP, Mugenyi P, Rinke de Wit TF, Kityo C. Barriers to Initiation of Pediatric HIV Treatment in Uganda: A Mixed-Method Study. *AIDS Res Treat*. 2012;2012:817506.

153. Lorenzana SB, Hughes MD, Grinsztejn B, Collier AC, Luz PM, Freedberg KA, Wood R, Levison JH, Mugenyi PN, Salata R, Wallis CL, Weinstein MC, Schooley RT, Walensky RP. Genotype assays and third-line ART in resource-limited settings: a simulation and cost-effectiveness analysis of a planned clinical trial. *AIDS*. 2012 Jun 1;26(9):1083-93.
154. Hamers RL, Schuurman R, Sigaloff KC, Wallis CL, Kityo C, Siwale M, Mandaliya K, Ive P, Botes ME, Wellington M, Osibogun A, Wit FW, van Vugt M, Stevens WS, de Wit TF; PharmAccess African Studies to Evaluate Resistance (PASER) Investigators. Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study. *Lancet Infect Dis*. 2012 Apr;12(4):307-17.
155. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS, Luetkemeyer AF, Hogg E, Rooney JF, Wu X, Hosseinipour MC, Lalloo U, Veloso VG, Some FF, Kumarasamy N, Padayatchi N, Santos BR, Reid S, Hakim J, Mohapi L, Mugenyi P, Sanchez J, Lama JR, Pape JW, Sanchez A, Asmelash A, Moko E, Sawe F, Andersen J, Sanne I; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. *N Engl J Med*. 2011 Oct 20;365(16):1482-91.
156. Wagner GJ, Ghosh-Dastidar B, Holloway IW, Kityo C, Mugenyi P. Depression in the pathway of HIV antiretroviral effects on sexual risk behavior among patients in Uganda. *AIDS Behav*. 2012 Oct;16(7):1862-9.
157. Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, Baseke J, Dobbs D, Stein CM, Mayanja H, Joloba M, Whalen CC, Boom WH. Innate and adaptive immune responses during acute *M. tuberculosis* infection in adult household contacts in Kampala, Uganda. *Am J Trop Med Hyg*. 2012 Apr;86(4):690-7
158. Christopher Muchwa, Joseph Akol, Alfred Etwom, Karen Morgan, Patrick Orikiriza, Francis Mumbowa, Paul R Odong, David P Kateete, Kathleen D Eisenach and Moses L Joloba. Evaluation of Capilia TB assay for rapid identification of *Mycobacterium tuberculosis* complex in BACTEC MGIT 960 and BACTEC 9120 blood cultures. *BMC Research Notes* 2012, 5:44
159. Steven J. Reynolds, Hakim Sendagire, Kevin Newell, Barbara Castelnuovo, Immaculate Nankya, Moses Kanya, Thomas C. Quinn, Yuka Manabe, Andrew

Kambugu. Virologic versus immunologic monitoring and the rate of accumulated genotypic resistance to first line antiretroviral drugs in Uganda. *BMC Infect Dis.* 2012 Dec 27;12(1):381. [Epub ahead of print] PMID: 23270482

160. Mahan CS, Zalwango S, Thiel BA, Malone LL, Chervenak KA, Baseke J, Dobbs D, Stein CM, Mayanja H, Joloba M, Whalen CC, Boom WH, Innate and adaptive immune responses during acute M. tuberculosis infection in adult household contacts in Kampala, Uganda. *Am J Trop Med Hyg.* 2012. 86(4):690-7.

161. Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Kabamba D, Asiiimwe A, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Gibb D. Differences in body circumferences, skin-fold thicknesses and lipid profiles among HIV-infected African children on and not on stavudine *J Int AIDS Soc.* 2012 Nov 11;15(6):18290. doi: 10.7448/IAS.15.6.18290

162. Gilks CF, Walker AS, Dunn DT, Gibb DM, Kikaire B, Reid A, Musana H, Mambule I, Kasirye R, Robertson V, Ssali F, Spyer M, Pillay D, Yirell D, Kaleebu P; DART Virology Group and Trial Team. Lopinavir/ritonavir monotherapy after 24 weeks of second-line antiretroviral therapy in Africa: a randomized controlled trial (SARA). *Antivir Ther.* 2012;17(7):1363-73. doi: 10.3851/IMP2253. Epub 2012 Jul 19.

163. Kasirye P, Kendall L, Adkison KK, Tumusiime C, Ssenyonga M, Bakeera-Kitaka S, Nahirya-Ntege P, Mhute T, Kekitiinwa A, Snowden W, Burger DM, Gibb DM, Walker AS; ARROW Trial Team. Pharmacokinetics of antiretroviral drug varies with formulation in the target population of children with HIV-1. *Clin Pharmacol Ther.* 2012 Feb;91(2):272-80. doi: 10.1038/clpt.2011.225. Epub 2011 Dec 21

164. Nahirya-Ntege P, Cook A, Vhembo T, Opilo W, Namuddu R, Katuramu R, Tezikyabbiri J, Naidoo-James B, Gibb D; ARROW Trial Team. Young HIV-infected children and their adult caregivers prefer tablets to syrup antiretroviral medications in Africa. *PLoS One.* 2012;7(5):e36186. doi:10.1371/journal.pone.0036186. Epub 2012 May 2

165. Performance of frontloading for smear microscopy in the diagnosis of pulmonary tuberculosis: a cross-sectional study at a referral hospital in Uganda. Mirembe P, Kalyango JN, Worodria W, Mugerwa H, Nakakawa E, Asiiimwe BB.

PLoS One. 2012;7(10):e48531. doi: 10.1371/journal.pone.0048531. Epub 2012 Oct 29.

Year 2013

166. [Pretreatment HIV-1 drug resistance in Africa.](#) Hamers RL, Kityo C, Sigaloff KC, de Wit TF. *Lancet Infect Dis.* 2013 Jun;13(6):476. doi: 10.1016/S1473-3099(13)70127-0.
167. [High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy.](#) Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Team. *Clin Infect Dis.* 2014 Apr;58(7):1023-6. doi: 10.1093/cid/cit933. Epub 2013 Dec 18.
168. [Clinical differences between younger and older adults with HIV/AIDS starting antiretroviral therapy in Uganda and Zimbabwe: a secondary analysis of the DART trial.](#) Parikh SM, Obuku EA, Walker SA, Semeere AS, Auerbach BJ, Hakim JG, Mayanja-Kizza H, Mugenyi PN, Salata RA, Kityo CM; DART Trial Team. *PLoS One.* 2013 Oct 2;8(10):e76158. doi: 10.1371/journal.pone.0076158. eCollection 2013.
169. [HIV-1 drug resistance in antiretroviral-naive patients in sub-Saharan Africa.](#) Hamers RL, Sigaloff KC, Kityo C, Mugenyi P, de Wit TF. *Lancet Infect Dis.* 2013 Mar;13(3):196-7. doi: 10.1016/S1473-3099(13)70012-4. No abstract available.
170. [Short communication: high rates of thymidine analogue mutations and dual-class resistance among HIV-infected Ugandan children failing first-line antiretroviral therapy.](#) Sigaloff KC, Kayiwa J, Musiime V, Calis JC, Kaudha E, Mukuye A, Matama C, Nankya I, Nakatudde L, Dekker JT, Hamers RL, Mugenyi P, Rinke De Wit TF, Kityo C. *AIDS Res Hum Retroviruses.* 2013 Jun;29(6):925-30. doi: 10.1089/AID.2012.0218. Epub 2013 Apr 17.
171. [Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial.](#) Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunanya J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team. *Antivir Ther.* 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25.

172. [Determinants of clinician knowledge on aging and HIV/AIDS: a survey of practitioners and policy makers in Kampala District, Uganda.](#)
Obuku EA, Parikh SM, Nankabirwa V, Kakande NI, Mafigiri DK, Mayanja-Kizza H, Kityo CM, Mugenyi PN, Salata RA.
PLoS One. 2013;8(2):e57028. doi: 10.1371/journal.pone.0057028. Epub 2013 Feb 28.
173. [Development and evaluation of an affordable real-time qualitative assay for determining HIV-1 virological failure in plasma and dried blood spots.](#)
Aitken SC, Kliphuis A, Bronze M, Wallis CL, Kityo C, Balinda S, Stevens W, Spieker N, de Oliveira T, Rinke de Wit TF, Schuurman R.
J Clin Microbiol. 2013 Jun;51(6):1899-905. doi: 10.1128/JCM.03305-12. Epub 2013 Apr 17.
174. [A single CD4 test with 250 cells/mm³ threshold predicts viral suppression in HIV-infected adults failing first-line therapy by clinical criteria.](#)
Gilks CF, Walker AS, Munderi P, Kityo C, Reid A, Katabira E, Goodall RL, Grosskurth H, Mugenyi P, Hakim J, Gibb DM; DART Virology Group and Trial Team.
PLoS One. 2013;8(2):e57580. doi: 10.1371/journal.pone.0057580. Epub 2013 Feb 21.
175. [Emerging HIV-1 drug resistance after roll-out of antiretroviral therapy in sub-Saharan Africa.](#)
Hamers RL, Sigaloff KC, Kityo C, Mugenyi P, de Wit TF.
Curr Opin HIV AIDS. 2013 Jan;8(1):19-26. doi: 10.1097/COH.0b013e32835b7f94. Review.
176. [Treatment failure and drug resistance is more frequent in HIV-1 subtype D versus subtype A-infected Ugandans over a 10-year study period.](#)
Kyeyune F, Nankya I, Metha S, Akao J, Ndashimye E, Tebit DM, Rodriguez B, Kityo C, Salata RA, Mugenyi P, Arts E; JCRC Drug Resistance Working Group.
AIDS. 2013 Jul 31;27(12):1899-909.
177. [Poor immunological recovery among severely immunosuppressed antiretroviral therapy-naïve Ugandans.](#)
Nanzigu S, Kiguba R, Kabanda J, Mukonzo JK, Waako P, Kityo C, Makumbi F.
HIV AIDS (Auckl). 2013 Dec 6;5:309-19. doi: 10.2147/HIV.S50614. eCollection 2013.
178. [Virological Response and Antiretroviral Drug Resistance Emerging during Antiretroviral Therapy at Three Treatment Centers in Uganda.](#)
Kaleebu P, Kirungi W, Watera C, Asio J, Lyagoba F, Lutalo T, Kapaata AA, Nanyonga F, Parry CM, Magambo B, Nazziwa J, Nannyonjo M, Hughes P, Hladik W, Ruberantwari A, Namuwenge N, Musinguzi J, Downing R, Katongole-Mbidde E; HIV Drug Resistance Working group. PLoS One. 2015 Dec 23;10(12):e0145536. doi: 10.1371/journal.pone.0145536. eCollection 2015.

179. [A pragmatic approach to HIV-1 drug resistance determination in resource-limited settings by use of a novel genotyping assay targeting the reverse transcriptase-encoding region only.](#) Aitken SC, Bronze M, Wallis CL, Stuyver L, Steegen K, Balinda S, Kityo C, Stevens W, Rinke de Wit TF, Schuurman R. *J Clin Microbiol.* 2013 Jun;51(6):1757-61. doi: 10.1128/JCM.00118-13. Epub 2013 Mar 27.
180. [Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children.](#) Musiime V, Kaudha E, Kayiwa J, Mirembe G, Odera M, Kizito H, Nankya I, Ssali F, Kityo C, Colebunders R, Mugenyi P. *AIDS Res Hum Retroviruses.* 2013 Mar;29(3):449-55. doi: 10.1089/aid.2012.0283. Epub 2013 Jan 11.
181. [Prospective cohort study of the impact of antiretroviral therapy on employment outcomes among HIV clients in Uganda.](#) Linnemayr S, Glick P, Kityo C, Mugenyi P, Wagner G. *AIDS Patient Care STDS.* 2013 Dec;27(12):707-14. doi: 10.1089/apc.2013.0139.
182. [Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART.](#) Kiwuwa-Muyingo S, Oja H, Walker A, Ilmonen P, Levin J, Mambule, Reid A, Mugenyi P, Todd J; DART Trial team. *BMC Infect Dis.* 2013 Aug 27;13:395. doi: 10.1186/1471-2334-13-395.
183. [Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment \(START\) trial.](#) Kunisaki KM, Niewoehner DE, Collins G, Aagaard B, Atako NB, Bakowska E, Clarke A, Corbelli GM, Ekong E, Emery S, Finley EB, Florence E, Infante RM, Kityo CM, Madero JS, Nixon DE, Tedaldi E, Vestbo J, Wood R, Connett JE; INSIGHT START Pulmonary Substudy Group. *Lancet Respir Med.* 2016 Dec;4(12):980-989. doi: 10.1016/S2213-2600(16)30319-8. Epub 2016 Oct 20.
184. [Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children \(CHAPAS-3\): an open-label, parallel-group, randomised controlled trial.](#) Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. *Lancet Infect Dis.* 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.
185. [Impact of decentralisation of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys.](#) Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team. *Int Health.* 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.

186. [Sustainable and cost-effective monitoring of patients on ART](#). Gibb DM, Mugenyi P. *Lancet Glob Health*. 2014 Jan;2(1):e4-5. doi: 10.1016/S2214-109X(13)70081-0. Epub 2013 Dec 10. No abstract available.
187. [Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV \(ARROW\): a 5-year open-label randomised factorial trial](#). ARROW Trial team, Kekitiinwa A, Cook A, Nathoo K, Mugenyi P, Nahirya-Ntege P, Bakeera-Kitaka S, Thomason M, Bwakura-Dangarembizi M, Musiime V, Munderi P, Naidoo-James B, Vhembo T, Tumusiime C, Katuramu R, Crawley J, Prendergast AJ, Musoke P, Walker AS, Gibb DM. *Lancet*. 2013 Apr 20;381(9875):1391-403. doi: 10.1016/S0140-6736(12)62198-9. Epub 2013 Mar 7.
188. [Bacteremia, causative agents and antimicrobial susceptibility among HIV-1-infected children on antiretroviral therapy in Uganda and Zimbabwe](#). Musiime V, Cook A, Bakeera-Kitaka S, Vhembo T, Lutakome J, Keishanyu R, Prendergast AJ, Lubwama S, Robertson V, Hughes P, Nathoo K, Munderi P, Klein N, Musoke P, Gibb DM; ARROW Trial Team. *Pediatr Infect Dis J*. 2013 Aug;32(8):856-62. doi: 10.1097/INF.0b013e31828c3991.
189. [Dynamic logistic regression model and population attributable fraction to investigate the association between adherence, missed visits and mortality: a study of HIV-infected adults surviving the first year of ART](#). Kiwuwa-Muyingo S, Oja H, Walker A, Ilmonen P, Levin J, Mambule, Reid A, Mugenyi P, Todd J; DART Trial team. *BMC Infect Dis*. 2013 Aug 27;13:395. doi: 10.1186/1471-2334-13-395.
190. [Predicting patterns of long-term CD4 reconstitution in HIV-infected children starting antiretroviral therapy in sub-Saharan Africa: a cohort-based modelling study](#). Picat MQ, Lewis J, Musiime V, Prendergast A, Nathoo K, Kekitiinwa A, Nahirya Ntege P, Gibb DM, Thiebaut R, Walker AS, Klein N, Callard R; ARROW Trial Team. *PLoS Med*. 2013 Oct;10(10):e1001542. doi: 10.1371/journal.pmed.1001542. Epub 2013 Oct 29.

2014 Publications

191. Musiime V, Cook A, Kayiwa J, Zangata D, Nansubuga C, Arach B, Kenny J, Wavamunno P, Komunanya J, Kabamba D, Asiimwe AR, Mirembe G, Abongomera G, Mulenga V, Kekitiinwa A, Kityo C, Walker SA, Klein N, Gibb DM; CHAPAS-3 trial team. [Anthropometric measurements and lipid profiles to detect early lipodystrophy in antiretroviral therapy experienced HIV-infected children in the CHAPAS-3 trial](#). *Antivir Ther*. 2014;19(3):269-76. doi: 10.3851/IMP2695. Epub 2013 Oct 25.

192. Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndemi N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Teams. [Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda](#). *J Antimicrob Chemother*. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14.
193. Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugenyi P, Walker AS, Dunn DT; DART Trial Team. [High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial](#). *PLoS One*. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014.
194. Jaganath D, Walker AS, Ssali F, Musiime V, Kiweewa F, Kityo C, Salata R, Mugenyi P. [HIV-Associated Anemia After 96 Weeks on Therapy: Determinants Across Age Ranges in Uganda and Zimbabwe](#). *AIDS Res Hum Retroviruses*. 2014 Jun;30(6):523-30. doi: 10.1089/aid.2013.0255. Epub 2014 Feb 7.
195. Gupta RK, Goodall RL, Ranopa M, Kityo C, Munderi P, Lyagoba F, Mugarura L, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Team. [High rate of HIV resuppression after viral failure on first-line antiretroviral therapy in the absence of switch to second-line therapy](#). *Clin Infect Dis*. 2014 Apr;58(7):1023-6. doi: 10.1093/cid/cit933. Epub 2013 Dec 18.
196. Nichols BE, Sigaloff KC, Kityo C, Mandaliya K, Hamers RL, Bertagnolio S, Jordan MR, Boucher CA, Rinke de Wit TF, van de Vijver DA. [Averted HIV infections due to expanded antiretroviral treatment eligibility offsets risk of transmitted drug resistance: a modeling study](#). *AIDS*. 2014 Jan 2;28(1):73-83. doi: 10.1097/01.aids.0000433239.01611.52.
197. Fillekes Q, Kendall L, Kitaka S, Mugenyi P, Musoke P, Ndigendawani M, Bwakura-Dangarembizi M, Gibb DM, Burger D, Walker AS; ARROW Trial Team. [Pharmacokinetics of zidovudine dosed twice daily according to World Health Organization weight bands in Ugandan HIV-infected children](#). *Pediatr Infect Dis J*. 2014 May;33(5):495-8. doi: 10.1097/INF.0000000000000143.

198. Boltz VF, Bao Y, Lockman S, Halvas EK, Kearney MF, McIntyre JA, Schooley RT, Hughes MD, Coffin JM, Mellors JW; OCTANE/A5208 Team. [Low-frequency nevirapine \(NVP\)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.](#) J Infect Dis. 2014 Mar 1;209(5):703-10. doi: 10.1093/infdis/jit635. Epub 2014 Jan 16.
199. Musiime V, Fillekes Q, Kekitiinwa A, Kendall L, Keishanyu R, Namuddu R, Young N, Opilo W, Lallemand M, Walker AS, Burger D, Gibb DM. [The pharmacokinetics and acceptability of lopinavir/ritonavir minitab sprinkles, tablets, and syrups in african HIV-infected children.](#) J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):148-54. doi: 10.1097/QAI.0000000000000135.
200. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, Nathoo K, Spyer MJ, Kekitiinwa A, Lutaakome J, Mhute T, Kasirye P, Munderi P, Musiime V, Gibb DM, Walker AS, Prendergast AJ; Antiretroviral Research for Watoto (ARROW) Trial Team. [A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa.](#) N Engl J Med. 2014 Jan 2;370(1):41-53. doi: 10.1056/NEJMoa1214901. Erratum in: N Engl J Med. 2014 Jan 30;370(5):488. Dosage error in article text.
201. Goodall RL, Dunn DT, Pattery T, van Cauwenberge A, Nkurunziza P, Awio P, Ndembu N, Munderi P, Kityo C, Gilks CF, Kaleebu P, Pillay D; DART Virology Group and Trial Teams. [Phenotypic and genotypic analyses to guide selection of reverse transcriptase inhibitors in second-line HIV therapy following extended virological failure in Uganda.](#) J Antimicrob Chemother. 2014 Jul;69(7):1938-44. doi: 10.1093/jac/dku052. Epub 2014 Mar 14.
202. Hamlyn E, Fidler S, Stöhr W, Cooper DA, Tambussi G, Schechter M, Miro JM, McClure M, Weber J, Babiker A, Porter K; SPARTAC Trial Investigators. [Interleukin-6 and D-dimer levels at seroconversion as predictors of HIV-1 disease progression.](#) AIDS. 2014 Mar 27;28(6):869-74. doi: 10.1097/QAD.0000000000000155.
203. Longosz AF¹, Morrison CS, Chen PL, Arts E, Nankya I, Salata RA, Franco V, Quinn TC, Eshleman SH, Laeyendecker O. [Immune responses in Ugandan women infected with subtypes A and D HIV using the BED capture immunoassay and an](#)

[antibody avidity assay.J Acquir Immune Defic Syndr.](#) 2014 Apr 1;65(4):390-6. doi: 10.1097/QAI.0000000000000006.

204. Kaye DK, Kakaire O, Nakimuli A, Osinde MO, Mbalinda SN, Kakande N. [Lived experiences of women who developed uterine rupture following severe obstructed labor in Mulago hospital, Uganda.](#) *Reprod Health.* 2014 Apr 22;11:31. doi: 10.1186/1742-4755-11-31.
205. Kaye DK, Kakaire O, Nakimuli A, Osinde MO, Mbalinda SN, Kakande N. [Male involvement during pregnancy and childbirth: men's perceptions, practices and experiences during the care for women who developed childbirth complications in Mulago Hospital, Uganda.](#) *BMC Pregnancy Childbirth.* 2014 Jan 31;14:54. doi: 10.1186/1471-2393-14-54.
206. Boulware DR, Meya DB, Muzoora C, Rolfes MA, Huppler Hullsiek K, Musubire A, Taseera K, Nabeta HW, Schutz C, Williams DA, Rajasingham R, Rhein J, Thienemann F, Lo MW, Nielsen K, Bergemann TL, Kambugu A, Manabe YC, Janoff EN, Bohjanen PR, Meintjes G; COAT Trial Team. [Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis.](#) *N Engl J Med.* 2014 Jun 26;370(26):2487-98. doi: 10.1056/NEJMoa1312884.
207. Robertson EJ, Najjuka G, Rolfes MA, Akampurira A, Jain N, Anantharanjit J, von Hohenberg M, Tassieri M, Carlsson A, Meya DB, Harrison TS, Fries BC, Boulware DR, Bicanic T. [Cryptococcus neoformans ex vivo capsule size is associated with intracranial pressure and host immune response in HIV-associated cryptococcal meningitis.](#) *J Infect Dis.* 2014 Jan 1;209(1):74-82. doi: 10.1093/infdis/jit435. Epub 2013 Aug 14.
208. Moses L. Joloba, John L. Johnson , Pei-Jean I. Feng, Lorna Bozeman, Stefan V. Goldberg, Karen Morgan, Phineas Gitta, Henry W. Boom , Charles M. Heilig, Harriet Mayanja-Kizza, Kathleen D. Eisenach. (2014), [What is the most reliable solid culture medium for tuberculosis treatment trials?](#) <http://dx.doi.org/10.1016/j.tube.2014.03.002>

209. Charles M. Heilig, Pei-Jean I. Feng, Moses L. Joloba, John L. Johnson ,Karen Morgan, Phineas Gitta, W. Henry Boom , Harriet Mayanja-Kizza,Kathleen D. Eisenach , Lorna Bozeman, Stefan V. Goldberg. (2014), [How we determined the most reliable solid medium for studying treatment of tuberculosis](http://dx.doi.org/10.1016/j.tube.2014.02.006) <http://dx.doi.org/10.1016/j.tube.2014.02.006>
210. Nicholas I. Paton, M.D., Cissy Kityo, M.Sc., Anne Hoppe, Ph.D., Andrew Reid, M.R.C.P., Andrew Kambugu, M.Med., Abbas Lugemwa, M.D., Joep J. van Oosterhout, Ph.D., Mary Kiconco, M.P.H., Abraham Siika, M.Med., Raymond Mwebaze, M.Med., Mary Abwola, M.Med., George Abongomera, M.Sc., Aggrey Mweemba, M.Med., Hillary Alima, M.P.H., Dickens Atwongyeire, M.B., Ch.B., Rose Nyirenda, M.Sc., Justine Boles, M.Sc., Jennifer Thompson, M.Sc., Dinah Tumukunde, M.P.H., Ennie Chidziva, Dipl.G.N., Ivan Mambule, M.B., Ch.B., Jose R. Arribas, M.D., Philippa J. Easterbrook, M.D., James Hakim, F.R.C.P., A. Sarah Walker, Ph.D., and Peter Mugenyi, F.R.C.P., for the EARNEST Trial Team [Assessment of Second-Line Antiretroviral Regimens for HIV Therapy in Africa](#) N Engl J Med 2014;371:234-47. DOI: 10.1056/NEJMoa1311274
211. Adrienne K Chan, Deborah Ford, Harriet Namata, Margaret Muzambi, Misheck J Nkhata, George Abongomera, Ivan Mambule, Annabelle South, Paul Revill, Caroline Grundy, Trevor Mabugu, Levison Chiwaula, Fabian Cataldo, James Hakim, Janet Seeley, Cissy Kityo, Andrew Reid, Elly Katabira, Sumeet Sodhi, Charles F Gilks and Diana M Gibb. [The Lablite project: A cross-sectional mapping survey of decentralized HIV service provision in Malawi, Uganda and Zimbabwe](#)
212. Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugenyi P, Nahirya P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; for the ARROW Trial Team. [Prevalence of Lipodystrophy and Metabolic Abnormalities in HIV-Infected African Children after Three Years on First-Line Antiretroviral Therapy](#) *Pediatr Infect Dis J.* 2014 Jul 25. [Epub ahead of print]

2015 Publications

213. [Communicating vaccine safety in the context of immunization programs in low resource settings.](#) Arwanire EM, Mbabazi W, Mugenyi P. *Curr Drug Saf.* 2015;10(1):68-75.

214. [Why START? Reflections that led to the conduct of this large long-term strategic HIV trial.](#) INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Study Group, Lundgren J, Babiker A, Gordin F, Emery S, Fätkenheuer G, Molina JM, Wood R, Neaton JD. HIV Med. 2015 Apr;16 Suppl 1:1-9. doi: 10.1111/hiv.12227. No abstract available.
215. [Opportunities for improving the efficiency of paediatric HIV treatment programmes.](#) Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahiryia-Ntege P, Walker AS, Sculpher MJ, Gibb DM. AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.
216. [Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.](#) Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugenyi P, Nahiryia P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.
217. [Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/ \$\mu\$ L: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment \(START\) trial.](#) Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE; International Network for Strategic Initiatives in Global HIV Trials (INSIGHT) START Study Group. HIV Med. 2015 Apr;16 Suppl 1:119-28. doi: 10.1111/hiv.12240.
218. [HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels.](#) Eller MA, Opollo MS, Liu M, Redd AD, Eller LA, Kityo C, Kayiwa J, Laeyendecker O, Wawer MJ, Milazzo M, Kiwanuka N, Gray RH, Serwadda D, Sewankambo NK, Quinn TC, Michael NL, Wabwire-Mangen F, Sandberg JK, Robb ML. J Infect Dis. 2015 May 15;211(10):1574-84. doi: 10.1093/infdis/jiu646. Epub 2014 Nov 17.

219. [Prevalence of hepatitis B and C and relationship to liver damage in HIV infected patients attending Joint Clinical Research Centre Clinic \(JCRC\), Kampala, Uganda.](#) Baseke J, Musenero M, Mayanja-Kizza H. *Afr Health Sci.* 2015 Jun;15(2):322-7. doi: 10.4314/ahs.v15i2.3.
220. [Inguinal lymph node and anorectal mucosal biopsies for human immunodeficiency virus research protocols in an emerging nation: patient outcomes and lessons learned.](#) Rothenberger MK, Mutuluza CK, Ssali F, Jasurda J, Schmidt T, Schacker TW, Beilman GJ, Chipman JG. *Surg Infect (Larchmt).* 2015 Feb;16(1):68-71. doi: 10.1089/sur.2013.179. Epub 2015 Feb 4.
221. [Partner-Focused Adherence Intervention for Second-line Antiretroviral Therapy: A Multinational Randomized Trial \(ACTG A5234\).](#) Gross R, Zheng L, La Rosa A, Sun X, Rosenkranz SL, Cardoso SW, Ssali F, Camp R, Godfrey C, Cohn SE, Robbins GK, Chisada A, Wallis CL, Reynolds NR, Lu D, Safren SA, Hosey L, Severe P, Collier AC. *Lancet HIV.* 2015 Jan 1;2(1):e12-e19.
222. [Disclosure of HIV Status to Perinatally Infected Adolescents in Urban Uganda: A Qualitative Study on Timing, Process, and Outcomes.](#) Mutumba M, Musiime V, Tsai AC, Byaruhanga J, Kiweewa F, Bauermeister JA, Snow RC. *J Assoc Nurses AIDS Care.* 2015 Jul-Aug;26(4):472-84. doi: 10.1016/j.jana.2015.02.001. Epub 2015 Feb 12.
223. [Pubertal development in HIV-infected African children on first-line antiretroviral therapy.](#) Szubert AJ, Musiime V, Bwakura-Dangarembizi M, Nahirya-Ntege P, Kekitiinwa A, Gibb DM, Nathoo K, Prendergast AJ, Walker AS; ARROW Trial Team. *AIDS.* 2015 Mar 13;29(5):609-18. doi: 10.1097/QAD.0000000000000590.
224. [Psychosocial challenges and strategies for coping with HIV among adolescents in Uganda: a qualitative study.](#) Mutumba M, Bauermeister JA, Musiime V, Byaruhanga J, Francis K, Snow RC, Tsai AC. *AIDS Patient Care STDS.* 2015 Feb;29(2):86-94. doi: 10.1089/apc.2014.0222. Epub 2015 Jan 21.
225. [Development of a psychosocial distress measure for Ugandan adolescents living with HIV.](#) Mutumba M, Resnicow K, Bauermeister JA, Harper GW, Musiime

V, Snow RC, Lepkowski JM. AIDS Behav. 2015 Feb;19(2):380-92. doi: 10.1007/s10461-014-0973-y.

226. [Opportunities for improving the efficiency of paediatric HIV treatment programmes.](#) Revill PA, Walker S, Mabugu T, Nathoo KJ, Mugenyi P, Kekitinwa A, Munderi P, Bwakura-Dangarembizi M, Musiime V, Bakeera-Kitaka S, Nahiryia-Ntege P, Walker AS, Sculpher MJ, Gibb DM. AIDS. 2015 Jan 14;29(2):201-10. doi: 10.1097/QAD.0000000000000518.
227. [Prevalence of lipodystrophy and metabolic abnormalities in HIV-infected African children after 3 years on first-line antiretroviral therapy.](#) Bwakura-Dangarembizi M, Musiime V, Szubert AJ, Prendergast AJ, Gomo ZA, Thomason MJ, Musarurwa C, Mugenyi P, Nahiryia P, Kekitiinwa A, Gibb DM, Walker AS, Nathoo K; ARROW Trial Team. Pediatr Infect Dis J. 2015 Feb;34(2):e23-31. doi: 10.1097/INF.0000000000000491.
228. [Comparison of antibody responses to HIV infection in Ugandan women infected with HIV subtypes A and D.](#) Longosz AF, Morrison CS, Chen PL, Brand HH, Arts E, Nankya I, Salata RA, Quinn TC, Eshleman SH, Laeyendecker O. AIDS Res Hum Retroviruses. 2015 Apr;31(4):421-7. doi: 10.1089/AID.2014.0081. Epub 2014 Nov 19.
229. [Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults.](#) [Sagara I](#), [Oduro AR](#), [Mulenga M](#), [Dieng Y](#), [Ogutu B](#), [Tiono AB](#), [Mugenyi P](#), [Sie A](#), [Wasunna M](#), [Kain KC](#), [Djimdé AA](#), [Sarkar S](#), [Chandra R](#), [Robbins J¹](#), [Dunne MW](#). [Malar J](#). 2014 Nov 25;13:458. doi: 10.1186/1475-2875-13-458
230. [The Impact of Different CD4 Cell-Count Monitoring and Switching Strategies on Mortality in HIV-Infected African Adults on Antiretroviral Therapy: An Application of Dynamic Marginal Structural Models.](#) Ford D, Robins JM, Petersen ML, Gibb DM, Gilks CF, Mugenyi P, Grosskurth H, Hakim J, Katabira E, Babiker AG, Walker AS; DART Trial Team. Am J Epidemiol. 2015 Oct 1;182(7):633-43. doi: 10.1093/aje/kwv083. Epub 2015 Aug 26.
231. [Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.](#) INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, Avihingsanon A, Cooper DA, Fätkenheuer G, Llibre JM, Molina

- JM, Munderi P, Schechter M, Wood R, Klingman KL, Collins S, Lane HC, Phillips AN, Neaton JD. *N Engl J Med.* 2015 Aug 27;373(9):795-807. doi: 10.1056/NEJMoa1506816. Epub 2015 Jul 20.
232. [Prevalence of latent rheumatic heart disease among HIV-infected children in Kampala, Uganda.](#) Gleason B, Mirembe G, Namuyonga J, Okello E, Lwabi P, Lubega I, Lubega S, Musiime V, Kityo C, Salata RA, Longenecker CT. *J Acquir Immune Defic Syndr.* 2015 Sep 18.
233. [Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.](#) Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. *PLoS One.* 2015 Sep 18;10(9):e0137834. doi: 10.1371/journal.pone.0137834. eCollection 2015.
234. [Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.](#) Sutherland KA, Goodall RL, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Thiltgen G, Gilks CF, Spyer M, Kityo C, Pillay D, Dunn D, Gupta RK. *AIDS Res Hum Retroviruses.* 2015 Oct;31(10):1032-7. doi: 10.1089/aid.2015.0138. Epub 2015 Aug 10.
235. [Pretreatment HIV Drug Resistance Increases Regimen Switches in Sub-Saharan Africa.](#) Boender TS, Hoenderboom BM, Sigaloff KC, Hamers RL, Wellington M, Shamu T, Siwale M, Labib Maksimos EE, Nankya I, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Ondoa P, Rinke de Wit TF. *Clin Infect Dis.* 2015 Aug 3. pii: civ656.
236. [Single-dose nevirapine exposure does not affect response to antiretroviral therapy in HIV-infected African children aged below 3 years.](#) Musoke P, Szubert AJ, Musiime V, Nathoo K, Nahirya-Ntege P, Mutasa K, Williams DE, Prendergast AJ, Spyer M, Walker AS, Gibb DM; ARROW Trial Team. *AIDS.* 2015 Aug 24;29(13):1623-32.
237. [Dynamics of immunoglobulin sequence diversity in HIV-1 infected individuals.](#) Hoehn KB, Gall A, Bashford-Rogers R, Fidler SJ, Kaye S, Weber JN,

McClure MO; SPARTAC Trial Investigators, Kellam P, Pybus OG. *Philos Trans R Soc Lond B Biol Sci.* 2015 Sep 5;370(1676). pii: 20140241. doi: 10.1098/rstb.2014.0241.

238. [Structured observations reveal slow HIV-1 CTL escape.](#) Roberts HE, Hurst J, Robinson N, Brown H, Flanagan P, Vass L, Fidler S, Weber J, Babiker A, Phillips RE, McLean AR, Frater J; SPARTAC trial investigators. *PLoS Genet.* 2015 Feb 2;11(2):e1004914. doi: 10.1371/journal.pgen.1004914. eCollection 2015 Feb.
239. [Differences in Clinical Manifestations of Acute and Early HIV-1 Infection between HIV-1 Subtypes in African Women.](#) Lemonovich TL, Watkins RR, Morrison CS, Kwok C, Chipato T, Musoke R, Arts EJ, Nankya I, Salata RA. *J Int Assoc Provid AIDS Care.* 2015 Sep;14(5):415-22. doi: 10.1177/2325957413504827. Epub 2013 Oct 8.
240. [Handheld echocardiography versus auscultation for detection of rheumatic heart disease.](#) Godown J, Lu JC, Beaton A, Sable C, Mirembe G, Sanya R, Aliku T, Yu S, Lwabi P, Webb CL, Ensing GJ. *Pediatrics.* 2015 Apr;135(4):e939-44. doi: 10.1542/peds.2014-2774. Epub 2015 Mar 16.
241. [The utility of handheld echocardiography for early rheumatic heart disease diagnosis: a field study.](#) Beaton A, Lu JC, Aliku T, Dean P, Gaur L, Weinberg J, Godown J, Lwabi P, Mirembe G, Okello E, Reese A, Shrestha-Astudillo A, Bradley-Hewitt T, Scheel J, Webb C, McCarter R, Ensing G, Sable C. *Eur Heart J Cardiovasc Imaging.* 2015 May;16(5):475-82. doi: 10.1093/ehjci/jeu296. Epub 2015 Jan.
242. [Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children \(CHAPAS-3\): an open-label, parallel-group, randomised controlled trial](#) Veronica Mulenga, Victor Musime, Adeodata Kekitiinwa, Adrian D Cook, George Abongomera, Julia Kenny, Chisala Chabala, Grace Mirembe, Alice Asiimwe, Ellen Owen-Powell, David Burger, Helen McIlleron, Nigel Klein, Chifumbe Chintu, Margaret J Thomason, Cissy Kityo, A Sarah Walker, Diana M Gibb, on behalf of the CHAPAS-3 trial team. www.thelancet.com/infection Published online October 6, 2015 [http://dx.doi.org/10.1016/S1473-3099\(15\)00319-9](http://dx.doi.org/10.1016/S1473-3099(15)00319-9)

243. [Population level usage of health services, and HIV testing and care, prior to decentralization of antiretroviral therapy in Agago District in rural Northern Uganda.](#) Abongomera G, Kiwuwa-Muyingo S, Reville P, Chiwaula L, Mabugu T, Phillips A, Katabira E, Musiime V, Gilks C, Chan A, Hakim J, Colebunders R, Kityo C, Gibb DM, Seeley J, Ford D; Lablite Project Team. BMC Health Serv Res. 2015 Nov 28;15(1):527. doi: 10.1186/s12913-015-1194-4.
244. [Neurocognitive function at first-line failure and on second-line antiretroviral therapy in Africa: Analyses from the EARNEST Trial.](#) Kambugu A, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker AS, Paton NI. J Acquir Immune Defic Syndr. 2015 Nov 16. [Epub ahead of print]
245. [Cardiac Dysfunction Among Ugandan HIV-Infected Children on Antiretroviral Therapy.](#) Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. Pediatr Infect Dis J. 2015 Nov 12. [Epub ahead of print]
246. [Draft Genome Sequences of Mycobacterium bovis BZ 31150 and Mycobacterium bovis B2 7505, Pathogenic Bacteria Isolated from Archived Captive Animal Bronchial Washes and Human Sputum Samples in Uganda.](#) Wanzala SI, Nakavuma J, Travis DA, Kia P, Ogwang S, Sreevatsan S. Genome Announc. 2015 Oct 8;3(5). pii: e01102-15. doi: 10.1128/genomeA.01102-15. PMID:26450718
247. [A cross-sectional study of the magnitude, barriers, and outcomes of HIV status disclosure among women participating in a perinatal HIV transmission study, "the Nevirapine Repeat Pregnancy study".](#) Kiweewa FM, Bakaki PM, McConnell MS, Musisi M, Namirembe C, Nakayiwa F, Kusasira F, Nakintu D, Mubiru MC, Musoke P, Fowler MG. BMC Public Health. 2015 Sep 29;15(1):988. doi: 10.1186/s12889-015-2345-6. PMID:26420040
248. [Using Exclusion-Based Sample Preparation \(ESP\) to Reduce Viral Load Assay Cost.](#) Berry SM, Pezzi HM, Williams ED, Loeb JM, Guckenberger DJ, Lavanway AJ, Puchalski AA, Kityo CM, Mugenyi PN, Graziano FM, Beebe DJ. PLoS One. 2015 Dec 2;10(12):e0143631. doi: 10.1371/journal.pone.0143631. eCollection 2015. PMID:26630135

2016 publications

249. [Neuroscience and awareness in the dying human brain: Implications for organ donation practices.](#) Rady MY, Verheijde JL. *J Crit Care.* 2016 Aug;34:121-3. doi: 10.1016/j.jcrc.2016.04.016. Epub 2016 Apr 26.
250. [Acceptability of lopinavir/r pellets \(minitabs\), tablets and syrups in HIV-infected children.](#) Kekitiinwa A, Musiime V, Thomason MJ, Mirembe G, Lallemand M, Nakalanzi S, Baptiste D, Walker AS, Gibb DM, Judd A. *Antivir Ther.* 2016 Apr 29. doi: 10.3851/IMP3054.
251. [HPV Involvement in Head and Neck Cancers: Comprehensive Assessment of Biomarkers in 3680 Patients.](#) Castellsagué X, Alemany L, Quer M, Halc G, Quirós B, Tous S, Clavero O, Alòs L, Biegner T, Szafarowski T, Alejo M, Holzinger D, Cadena E, Claros E, Hall G, Laco J, Poljak M, Benevolo M, Kasamatsu E, Mehanna H, Ndiaye C, Guimerà N, Lloveras B, León X, Ruiz-Cabezas JC, Alvarado-Cabrero I, Kang CS, Oh JK, Garcia-Rojo M, Iljazovic E, Ajayi OF, Duarte F, Nessa A, Tinoco L, Duran-Padilla MA, Pirog EC, Viarheichyk H, Morales H, Costes V, Félix A, Germar MJ, Mena M, Ruacan A, Jain A, Mehrotra R, Goodman MT, Lombardi LE, Ferrera A, Malami S, Albanesi EI, Dabed P, Molina C, López-Revilla R, Mandys V, González ME, Velasco J, Bravo IG, Quint W, Pawlita M, Muñoz N, de Sanjosé S, Xavier Bosch F; ICO International HPV in Head and Neck Cancer Study Group. *J Natl Cancer Inst.* 2016 Jan 28;108(6):d403. doi: 10.1093/jnci/d403. Print 2016 Jun.
252. [HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.](#) Kityo C, Sigaloff KC, Sonia Boender T, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde-Katumba L, Calis JC, Rinke de Wit TF, Mugenyi PN. *AIDS Res Hum Retroviruses.* 2016 Jul;32(7):628-35. doi: 10.1089/AID.2015.0215. Epub 2016 Feb 11.
253. [Neurocognitive Function at the First-Line Failure and on the Second-Line Antiretroviral Therapy in Africa: Analyses From the EARNEST Trial.](#) Kambugu A, Thompson J, Hakim J, Tumukunde D, van Oosterhout JJ, Mwebaze R, Hoppe A, Abach J, Kwobah C, Arenas-Pinto A, Walker SA, Paton NI; EARNEST Trial Team. *J Acquir Immune Defic Syndr.* 2016 Apr 15;71(5):506-13. doi: 10.1097/QAI.0000000000000898.
254. [Cardiac Dysfunction Among Ugandan HIV-infected Children on Antiretroviral Therapy.](#) Namuyonga J, Lubega S, Musiime V, Lwabi P, Lubega I. *Pediatr Infect Dis J.* 2016 Mar;35(3):e85-8. doi: 10.1097/INF.0000000000000997.

255. [Peripheral neuropathy in HIV patients in sub-Saharan Africa failing first-line therapy and the response to second-line ART in the EARNEST trial.](#) Arenas-Pinto A, Thompson J, Musoro G, Musana H, Lugemwa A, Kambugu A, Mweemba A, Atwongyeire D, Thomason MJ, Walker AS, Paton NI; EARNEST Trial Team. *J Neurovirol.* 2016 Feb;22(1):104-13. doi: 10.1007/s13365-015-0374-7. Epub 2015 Aug 25.
256. [Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.](#) Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P. *J Antimicrob Chemother.* 2016 Oct 5. pii: dkw388.
257. [Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.](#) Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KC, Calis JC. *J Trop Pediatr.* 2016 Sep 15. pii: fmw062.
258. [Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women \(WAVES\): a randomised, controlled, double-blind, phase 3 study.](#) Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. *Lancet HIV.* 2016 Sep;3(9):e410-20. doi: 10.1016/S2352-3018(16)30016-9. Epub 2016 May 27.
259. [Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.](#) Boender TS, Hamers RL, Ondo P, Wellington M, Chimbetete C, Siwale M, Labib Maksimos EE, Balinda SN, Kityo CM, Adeyemo TA, Akanmu AS, Mandaliya K, Botes ME, Stevens W, Rinke de Wit TF, Sigaloff KC. *J Infect Dis.* 2016 Sep 15;214(6):873-83. doi: 10.1093/infdis/jiw219. Epub 2016 Jul 11.
260. [Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.](#) Boender TS, Kityo CM, Boerma RS, Hamers RL, Ondo P, Wellington M, Siwale M, Nankya I, Kaudha E, Akanmu AS, Botes ME, Steegen K, Calis JC, Rinke de Wit TF, Sigaloff KC. *J Antimicrob Chemother.* 2016 Oct;71(10):2918-27. doi: 10.1093/jac/dkw218. Epub 2016 Jun 23.
261. [Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial.](#) Sutherland KA, Parry CM, McCormick A, Kapaata A, Lyagoba F, Kaleebu P, Gilks CF, Goodall R, Spyer M, Kityo C, Pillay D, Gupta RK; DART Virology Group. *PLoS One.* 2016 Jun 2;11(6):e0157094. doi: 10.1371/journal.pone.0157094. eCollection 2016.
262. [Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.](#) Bienczak A, Denti P, Cook A, Wiesner L, Mulenga

- V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. J Acquir Immune Defic Syndr. 2016 Oct 1;73(2):161-8. doi: 10.1097/QAI.0000000000001032.
263. [Identification of gaps for implementation science in the HIV prevention, care and treatment cascade; a qualitative study in 19 districts in Uganda.](#) Bajunirwe F, Tumwebaze F, Abongomera G, Akakimpa D, Kityo C, Mugenyi PN. BMC Res Notes. 2016 Apr 14;9:217. doi: 10.1186/s13104-016-2024-4.
264. [Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.](#) Kyeyune F, Gibson RM, Nankya I, Venner C, Metha S, Akao J, Ndashimye E, Kityo CM, Salata RA, Mugenyi P, Arts EJ, Quiñones-Mateu ME. Antimicrob Agents Chemother. 2016 May 23;60(6):3380-97. doi: 10.1128/AAC.00038-16. Print 2016 Jun.
265. [The impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African children.](#) Bienczak A, Cook A, Wiesner L, Olagunju A, Mulenga V, Kityo C, Kekitiinwa A, Owen A, Walker AS, Gibb DM, McIlleron H, Burger D, Denti P. Br J Clin Pharmacol. 2016 Jul;82(1):185-98. doi: 10.1111/bcp.12934. Epub 2016 Apr 25.
266. [Clinical Evaluation of an Affordable Qualitative Viral Failure Assay for HIV Using Dried Blood Spots in Uganda.](#) Balinda SN, Ondo P, Obuku EA, Kliphuis A, Egau I, Bronze M, Kasambula L, Schuurman R, Spieker N, Rinke de Wit TF, Kityo C; ART-A consortium. PLoS One. 2016 Jan 29;11(1):e0145110. doi: 10.1371/journal.pone.0145110. eCollection 2016.
267. [Abacavir, zidovudine, or stavudine as paediatric tablets for African HIV-infected children \(CHAPAS-3\): an open-label, parallel-group, randomised controlled trial.](#) Mulenga V, Musiime V, Kekitiinwa A, Cook AD, Abongomera G, Kenny J, Chabala C, Mirembe G, Asiimwe A, Owen-Powell E, Burger D, McIlleron H, Klein N, Chintu C, Thomason MJ, Kityo C, Walker AS, Gibb DM; CHAPAS-3 trial team. Lancet Infect Dis. 2016 Feb;16(2):169-79. doi: 10.1016/S1473-3099(15)00319-9. Epub 2015 Oct 5.
268. [Brief Report: Prevalence of Latent Rheumatic Heart Disease Among HIV-Infected Children in Kampala, Uganda.](#) Gleason B, Mirembe G, Namuyonga J, Okello E, Lwabi P, Lubega I, Lubega S, Musiime V, Kityo C, Salata RA, Longenecker CT. J Acquir Immune Defic Syndr. 2016 Feb 1;71(2):196-9. doi: 10.1097/QAI.0000000000000827.
269. [Reduced bacterial skin infections in HIV-infected African children randomized to long-term cotrimoxazole prophylaxis.](#) Prendergast AJ, Bwakura-Dangarembizi M, Mugenyi P, Lutaakome J, Kekitiinwa A, Thomason MJ, Gibb DM, Walker AS; ARROW Trial Team. AIDS. 2016 Sep 20.
270. [Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection.](#) Borges ÁH, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugenyi P, Domingo P, Hoffmann C, Read TR, Pujari S, Meulbroek

M, Johnson M, Wilkin T, Mitsuyasu R; INSIGHT START Study Group. Clin Infect Dis. 2016 Sep 8. pii: ciw621.

271. [Affordable HIV drug-resistance testing for monitoring of antiretroviral therapy in sub-Saharan Africa.](#) Inzaule SC, Ondoa P, Peter T, Mugenyi PN, Stevens WS, de Wit TF, Hamers RL. Lancet Infect Dis. 2016 Aug 25. pii: S1473-3099(16)30118-9. doi: 10.1016/S1473-3099(16)30118-9.
272. [Baseline Inflammatory Biomarkers Identify Subgroups of HIV-Infected African Children With Differing Responses to Antiretroviral Therapy.](#) Prendergast AJ, Szubert AJ, Berejena C, Pimundu G, Pala P, Shonhai A, Musiime V, Bwakura-Dangarembizi M, Poulosom H, Hunter P, Musoke P, Kihembo M, Munderi P, Gibb DM, Spyer M, Walker AS, Klein N; ARROW Trial Team. J Infect Dis. 2016 Jul 15;214(2):226-36. doi: 10.1093/infdis/jiw148. Epub 2016 May 18.
273. [Empirical tuberculosis therapy versus isoniazid in adult outpatients with advanced HIV initiating antiretroviral therapy \(REMEMBER\): a multicountry open-label randomised controlled trial.](#) Hosseinipour MC, Bisson GP, Miyahara S, Sun X, Moses A, Riviere C, Kirui FK, Badal-Faesen S, Lagat D, Nyirenda M, Naidoo K, Hakim J, Mugenyi P, Henostroza G, Leger PD, Lama JR, Mohapi L, Alave J, Mave V, Veloso VG, Pillay S, Kumarasamy N, Bao J, Hogg E, Jones L, Zolopa A, Kumwenda J, Gupta A; Adult AIDS Clinical Trials Group A5274 (REMEMBER) Study Team. Lancet. 2016 Mar 19;387(10024):1198-209. doi: 10.1016/S0140-6736(16)00546-8.
274. [Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy.](#) Crook AM, Turkova A, Musiime V, Bwakura-Dangarembizi M, Bakeera-Kitaka S, Nahiryia-Ntege P, Thomason M, Mugenyi P, Musoke P, Kekitiinwa A, Munderi P, Nathoo K, Prendergast AJ, Walker AS, Gibb DM; ARROW Trial Team. BMC Med. 2016 Mar 23;14:50. doi: 10.1186/s12916-016-0593-7.
275. [Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.](#) Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KC, Calis JC. J Trop Pediatr. 2016 Sep 15. pii: fmw062.
276. [Examining the relationship between psychological distress and adherence to anti-retroviral therapy among Ugandan adolescents living with HIV.](#) Mutumba M, Musiime V, Lepkwoski JM, Harper GW, Snow RC, Resnicow K, Bauermeister JA. AIDS Care. 2016 Jul;28(7):807-15. doi: 10.1080/09540121.2015.1131966. Epub 2016 Jan 10.
277. [Once vs twice-daily abacavir and lamivudine in African children.](#) Musiime V, Kasirye P, Naidoo-James B, Nahiryia-Ntege P, Mhute T, Cook A, Mugarura L, Munjoma M, Thoofer NK, Ndashimye E, Nankya I, Spyer MJ, Thomason MJ,

Snowden W, Gibb DM, Walker AS; ARROW Trial Team. AIDS. 2016 Jul 17;30(11):1761-70. doi: 10.1097/QAD.0000000000001116.

278. [Can abacavir be used safely in children without HLA testing?](#) Musiime V, Prendergast AJ. Lancet HIV. 2016 Feb;3(2):e58-9. doi: 10.1016/S2352-3018(15)00228-3. Epub 2015 Dec 7. No abstract available.

2017 Publications

279. [Multicentre analysis of second-line antiretroviral treatment in HIV-infected children: adolescents at high risk of failure.](#) Boerma RS, Bunupuradah T, Dow D, Fokam J, Kariminia A, Lehman D, Kityo C, Musiime V, Palumbo P, Schoffelen A, Sophan S, Zandoni B, Rinke de Wit TF, Calis JCJ, Sigaloff KCE; Paediatric Second-line Study Group. Int AIDS Soc. 2017 Sep 15;20(1):21930. doi: 10.7448/IAS.20.1.21930.
280. [Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV \(EARNEST\): 144-week follow-up results from a randomised controlled trial.](#) Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. Lancet Infect Dis. 2017 Nov 3. pii: S1473-3099(17)30630-8. doi: 10.1016/S1473-3099(17)30630-8
281. [Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.](#) Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. N Engl J Med. 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.
282. [Universal antiretroviral therapy for HIV-infected children: a review of the benefits and risks to consider during implementation.](#) Barlow-Mosha L, Musiime V, Davies MA, Prendergast AJ, Musoke P, Siberry G, Penazzato M. J Int AIDS Soc. 2017 Jun 27;20(1):21552. doi: 10.7448/IAS.20.1.21552.
283. [Pretreatment HIV drug resistance results in virological failure and accumulation of additional resistance mutations in Ugandan children.](#) Kityo C, Boerma RS, Sigaloff KCE, Kaudha E, Calis JCJ, Musiime V, Balinda S, Nakanjako R, Boender TS, Mugenyi PN, Rinke de Wit TF. J Antimicrob Chemother. 2017 Sep 1;72(9):2587-2595. doi: 10.1093/jac/dkx188.
284. [Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.](#) Kekitiinwa A, Szubert AJ, Spyer M, Katuramu R, Musiime V, Mhute T, Bakeera-Kitaka S, Senfuma O, Walker AS, Gibb

DM; ARROW Trial Team. *Pediatr Infect Dis J*. 2017 Jun;36(6):588-594.
doi:10.1097/INF.0000000000001505.

285. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugenyi P, Walker AS; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *Lancet HIV*. 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub2017 May 8.
286. Unmet needs persist in pediatric HIV programs: lessons from selected case studies in Uganda. Orikiiriza J, Nakawesi J, Kikaire B, Turitwenka D, Schleich W, Kambugu A, Lamorde M, Normark J, Hennessy M, Musiime V, Rujumba J, Ndeezi G, Tumwesigye NM, Doherty DG, Achan J. *AIDS*. 2017 May 15;31(8):1196-1199. doi: 10.1097/QAD.0000000000001436. No abstract available.
287. Impact of decentralization of antiretroviral therapy services on HIV testing and care at a population level in Agago District in rural Northern Uganda: results from the Lablite population surveys. Abongomera G, Kiwuwa-Muyingo S, Revill P, Chiwaula L, Mabugu T, Phillips AN, Katabira E, Chan AK, Gilks C, Musiime V, Hakim J, Kityo C, Colebunders R, Gibb DM, Seeley J, Ford D; Lablite Project Team. *Int Health*. 2017 Mar 1;9(2):91-99. doi: 10.1093/inthealth/ihx006.
288. Psychological distress among Ugandan adolescents living with HIV: Examining stressors and the buffering role of general and religious coping strategies. Mutumba M, Bauermeister JA, Harper GW, Musiime V, Lepkowski J, Resnicow K, Snow RC. *Glob Public Health*. 2017 Dec;12(12):1479-1491. doi: 10.1080/17441692.2016.1170871. Epub 2016 Apr 11.
289. Insulin Resistance and Markers of Inflammation in HIV-infected Ugandan Children in the CHAPAS-3 Trial. Dirajlal-Fargo S, Musiime V, Cook A, Mirembe G, Kenny J, Jiang Y, Debanne S, Klein N, McComsey GA. *Pediatr Infect Dis J*. 2017 Aug;36(8):761-767. doi: 10.1097/INF.0000000000001544.
290. Improved Adherence to Antiretroviral Therapy Observed Among HIV-Infected Children Whose Caregivers had Positive Beliefs in Medicine in Sub-Saharan Africa. Abongomera G, Cook A, Musiime V, Chabala C, Lamorde M, Abach J, Thomason M, Mulenga V, Kekitiinwa A, Colebunders R, Kityo C, Walker AS, Gibb DM. *AIDS Behav*. 2017 Feb;21(2):441-449. doi: 10.1007/s10461-016-1582-8.
291. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. *J Trop Pediatr*. 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: *J Trop Pediatr*. 2016 Oct 15;:null.

292. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A, Agutu C, Walker S, Pett SL, Bwakura-Dangarembizi M, Lugemwa A, Kaunda S, Karoney M, Musoro G, Kabahenda S, Nathoo K, Maitland K, Griffiths A, Thomason MJ, Kityo C, Mugenyi P, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. *N Engl J Med.* 2017 Jul 20;377(3):233-245. doi: 10.1056/NEJMoa1615822.
293. Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. Paton NI, Kityo C, Thompson J, Nankya I, Bagenda L, Hoppe A, Hakim J, Kambugu A, van Oosterhout JJ, Kiconco M, Bertagnolio S, Easterbrook PJ, Mugenyi P, Walker AS; Europe
294. Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *Lancet HIV.* 2017 Aug;4(8):e341-e348. doi: 10.1016/S2352-3018(17)30065-6. Epub 2017 May 8.
295. The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data. Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group. *BMC Infect Dis.* 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3.
296. HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *Acquir Immune Defic Syndr.* 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.
297. Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance. Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. *J Trop Pediatr.* 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: *J Trop Pediatr.* 2016 Oct 15;:null.
298. monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *Lancet Infect Dis.* 2017 Nov 3. pii: S1473-3099(17)30630-8. doi: 10.1016/S1473-3099(17)30630-8.

299. [Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women \(Option B+\) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience.](#) Ford D, Muzambi M, Nkhata MJ, Abongomera G, Joseph S, Ndlovu M, Mabugu T, Grundy C, Chan AK, Cataldo F, Kityo C, Seeley J, Katabira E, Gilks CF, Reid A, Hakim J, Gibb DM; Lablite Team. *J Acquir Immune Defic Syndr.* 2017 Apr 15;74(5):508-516. doi: 10.1097/QAI.0000000000001267.
300. [HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa.](#) Kityo C, Thompson J, Nankya I, Hoppe A, Ndashimye E, Warambwa C, Mambule I, van Oosterhout JJ, Wools-Kaloustian K, Bertagnolio S, Easterbrook PJ, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *J Acquir Immune Defic Syndr.* 2017 Jun 1;75(2):e45-e54. doi: 10.1097/QAI.0000000000001285.
301. [HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.](#) Hoppe A, Giuliano M, Lugemwa A, Thompson JA, Florida M, Walker AS, Senoga I, Abwola MC, Pirillo MF, Kityo CM, Arenas-Pinto A, Paton NI; EARNEST Trial Team. *Antivir Ther.* 2017 Oct 11. doi: 10.3851/IMP3200. [Epub ahead of print] PMID:29021409.
302. [Second-line HIV Treatment in Ugandan Children: Favorable Outcomes and No Protease Inhibitor Resistance.](#) Boerma RS, Kityo C, Boender TS, Kaudha E, Kayiwa J, Musiime V, Mukuye A, Kiconco M, Nankya I, Nakatudde L, Mugenyi PN, Boele van Hensbroek M, Rinke de Wit TF, Sigaloff KCE, Calis JCJ. *J Trop Pediatr.* 2017 Apr 1;63(2):135-143. doi: 10.1093/tropej/fmw062. Erratum in: *J Trop Pediatr.* 2016 Oct 15;:null.
303. [Factors influencing cigarette smoking among soldiers and costs of soldier smoking in the work place at Kakiri Barracks, Uganda.](#) Basaza R, Otieno E, Musinguzi A, Mugenyi P, Haddock CK. *Tob Control.* 2017 May;26(3):330-333. doi: 10.1136/tobaccocontrol-2015-052878. Epub 2016 May 10.
304. [Long-Term Antiretroviral Treatment Adherence in HIV-Infected Adolescents and Adults in Uganda: A Qualitative Study.](#) Inzaule SC, Hamers RL, Kityo C, Rinke de Wit TF, Roura M. *PLoS One.* 2017 Feb 8;12(2):e0172077. doi: 10.1371/journal.pone.0172077. eCollection2017. PMID:28178336
305. [Rapid accumulation of HIV-1 thymidine analogue mutations and phenotypic impact following prolonged viral failure on zidovudine-based first-line ART in sub-Saharan Africa](#) Goodall RL, Dunn DT, Nkurunziza P, Mugarura L, Pattery T, Munderi P, Kityo C, Gilks C, Kaleebu P, Pillay D, Gupta RK; DART Virology Group. *J Antimicrob Chemother.* 2017 May 1;72(5):1450-1455. doi: 10.1093/jac/dkw583. PMID:28160504.
306. [Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets.](#) Bienczak A, Denti

P, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Gibb DM, Burger D, Walker AS, McIlleron H. *AIDS*. 2017 Apr 24;31(7):905-915. doi: 10.1097/QAD.0000000000001376.PMID:28060017.

307. [Effect of diurnal variation, CYP2B6 genotype and age on the pharmacokinetics of nevirapine in African children.](#) Bienczak A, Cook A, Wiesner L, Mulenga V, Kityo C, Kekitiinwa A, Walker AS, Owen A, Gibb DM, Burger D, McIlleron H, Denti P.J *Antimicrob Chemother*. 2017 Jan;72(1):190-199. Epub 2016 Oct 5.PMID:27707991.
308. [Adherence to antiretroviral therapy for HIV in sub-Saharan Africa and Asia: a comparative analysis of two regional cohorts.](#) Bijker R, Jiamsakul A, Kityo C, Kiertiburanakul S, Siwale M, Phanuphak P, Akanmu S, Chaiwarith R, Wit FW, Sim BL, Boender TS, Ditangco R, Rinke De Wit TF, Sohn AH, Hamers RL.J *Int AIDS Soc*. 2017 Mar 3;20(1):1-10. doi: 10.7448/IAS.20.1.21218.PMID:28362063
309. [Defining total-body AIDS-virus burden with implications for curative strategies.](#) Estes JD, Kityo C, Ssali F, Swainson L, Makamdop KN, Del Prete GQ, Deeks SG, Luciw PA, Chipman JG, Beilman GJ, Hoskuldsson T, Khoruts A, Anderson J, Deleage C, Jasurda J, Schmidt TE, Hafertepe M, Callisto SP, Pearson H, Reimann T, Schuster J, Schoepfoerster J, Southern P, Perkey K, Shang L, Wietgreffe SW, Fletcher CV, Lifson JD, Douek DC, McCune JM, Haase AT, Schacker TW. *Nat Med*. 2017 Oct 2. doi: 10.1038/nm.4411.
310. [Hepatitis B serological markers and plasma DNA concentrations.](#) Price H, Dunn D, Zachary T, Vudriko T, Chirara M, Kityo C, Munderi P, Spyer M, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. *AIDS*. 2017 May 15;31(8):1109-1117. doi: 10.1097/QAD.0000000000001454.PMID:28328795
- 2018
311. [Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial.](#) Siika A, McCabe L, Bwakura-Dangarembizi M, Kityo C, Mallewa J, Berkley J, Maitland K, Griffiths A, Baleeta K, Mudzingwa S, Abach J, Nathoo K, Thomason MJ, Prendergast AJ, Walker AS, Gibb DM; REALITY Trial Team. *Clin Infect Dis*. 2018 Mar 4;66(suppl_2):S140-S146. doi: 10.1093/cid/cix1142. PMID:29514235
312. [Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV \(EARNEST\): 144-week follow-up results from a randomised controlled trial.](#) Hakim JG, Thompson J, Kityo C, Hoppe A, Kambugu A, van Oosterhout JJ, Lugemwa A, Siika A, Mwebaze R, Mweemba A, Abongomera G, Thomason MJ, Easterbrook P, Mugenyi P, Walker AS, Paton NI; Europe Africa Research Network for Evaluation of Second-line Therapy (EARNEST) Trial Team. *Lancet Infect Dis*. 2018 Jan;18(1):47-57. doi: 10.1016/S1473-3099(17)30630-8. Epub 2017 Nov 3.PMID:29108797

313. [HIV-1 viral load and resistance in genital secretions in patients taking protease-inhibitor-based second-line therapy in Africa.](#) Hoppe A, Giuliano M, Lugemwa A, Thompson JA, Florida M, Walker AS, Senoga I, Abwola MC, Pirillo MF, Kityo CM, Arenas-Pinto A, Paton NI; EARNEST Trial Team. *Antivir Ther.* 2018;23(2):191-195. doi: 10.3851/IMP3200. PMID:29021409.
314. [Brief Report: Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide \(E/C/F/TAF\) in Virologically Suppressed Women.](#) Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. *J Acquir Immune Defic Syndr.* 2018 Jun 1;78(2):209-213. doi: 10.1097/QAI.0000000000001663. PMID:29481486
315. [A Human-Centered Approach to CV Care: Infrastructure Development in Uganda.](#) Longenecker CT, Kalra A, Okello E, Lwabi P, Omagino JO, Kityo C, Kanya MR, Webel AR, Simon DI, Salata RA, Costa MA. *Glob Heart.* 2018 Apr 20. pii: S2211-8160(18)30022-X. doi: 10.1016/j.ghheart.2018.02.002. [Epub ahead of print] PMID:29685638
316. [Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.](#) Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugenyi P, Quiñones-Mateu ME, Arts EJ. *AIDS Res Hum Retroviruses.* 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26. PMID:29353487
317. [Lymphoid tissue fibrosis is associated with impaired vaccine responses.](#) Kityo C, Makamdop KN, Rothenberger M, Chipman JG, Hoskuldsson T, Beilman GJ, Grzywacz B, Mugenyi P, Ssali F, Akondy RS, Anderson J, Schmidt TE, Reimann T, Callisto SP, Schoephoerster J, Schuster J, Muloma P, Ssengendo P, Moysi E, Petrovas C, Lanciotti R, Zhang L, Arévalo MT, Rodriguez B, Ross TM, Trautmann L, Sekaly RP, Lederman MM, Koup RA, Ahmed R, Reilly C, Douek DC, Schacker TW. *J Clin Invest.* 2018 May 21. pii: 97377. doi: 10.1172/JCI97377. [Epub ahead of print] PMID:29781814
318. [Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa.](#) Kroeze S, Ondoa P, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, de Pundert ME, Sigaloff KCE, Reiss P, Wit FWNM, Rinke de Wit TF, Hamers RL. *AIDS.* 2018 May 15;32(8):1043-1051. doi: 10.1097/QAD.0000000000001801 PMID:29547445
319. [Patient-level benefits associated with decentralization of antiretroviral therapy services to primary health facilities in Malawi and Uganda.](#) Abongomera G, Chiwaula L, Revill P, Mabugu T, Tumwesige E, Nkhata M, Cataldo F, van Oosterhout J, Colebunders R, Chan AK, Kityo C, Gilks C, Hakim J, Seeley J, Gibb DM, Ford D. *Int Health.* 2018 Jan 1;10(1):8-19. doi: 10.1093/inthealth/ihx061. PMID:29329396

320. [Towards 90-90-90 Target: Factors Influencing Availability, Access, and Utilization of HIV Services-A Qualitative Study in 19 Ugandan Districts.](#) Bajunirwe F, Tumwebaze F, Akakimpa D, Kityo C, Mugenyi P, Abongomera G. *Biomed Res Int.* 2018 Mar 21;2018:9619684. doi: 10.1155/2018/9619684. eCollection 2018. PMID:29750175
321. [She knows that she will not come back: tracing patients and new thresholds of collective surveillance in PMTCT Option B.](#) Cataldo F, Seeley J, Nkhata MJ, Mupambireyi Z, Tumwesige E, Gibb DM; Lablite team. *BMC Health Serv Res.* 2018 Feb 1;18(1):76. doi: 10.1186/s12913-017-2826-7. PMID:29391055
322. [Effect of ready-to-use supplementary food on mortality in severely immunocompromised HIV-infected individuals in Africa initiating antiretroviral therapy \(REALITY\): an open-label, parallel-group, randomised controlled trial.](#) Mallewa J, Szubert AJ, Mugenyi P, Chidziva E, Thomason MJ, Chepkorir P, Abongomera G, Baleeta K, Etyang A, Warambwa C, Melly B, Mudzingwa S, Kelly C, Agutu C, Wilkes H, Nkomani S, Musiime V, Lugemwa A, Pett SL, Bwakura-Dangarembizi M, Prendergast AJ, Gibb DM, Walker AS, Berkley JA; REALITY trial team. *Lancet HIV.* 2018 May;5(5):e231-e240. doi: 10.1016/S2352-3018(18)30038-9. Epub 2018 Apr 10. Erratum in: [Lancet HIV. 2018 May 29.](#) PMID:29653915
323. [Causes and Timing of Mortality and Morbidity Among Late Presenters Starting Antiretroviral Therapy in the REALITY Trial.](#) Post FA, Szubert AJ, Prendergast AJ, Johnston V, Lyall H, Fitzgerald F, Musiime V, Musoro G, Chepkorir P, Agutu C, Mallewa J, Rajapakse C, Wilkes H, Hakim J, Mugenyi P, Walker AS, Gibb DM, Pett SL; Reduction of EARly mortaLITY in HIV-infected adults and children starting antiretroviral therapy (REALITY) Trial Team . *Clin Infect Dis.* 2018 Mar 4;66(suppl_2):S132-S139. doi: 10.1093/cid/cix1141. PMID:29514234
324. [When prevention of mother-to-child HIV transmission fails: preventing pretreatment drug resistance in African children.](#) Inzaule SC, Hamers RL, Calis J, Boerma R, Sigaloff K, Zeh C, Mugenyi P, Akanmu S, Rinke de Wit TF. *AIDS.* 2018 Jan 14;32(2):143-147. doi: 10.1097/QAD.0000000000001696. No abstract available. PMID:29135578
325. [Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection.](#) Klein K, Nickel G, Nankya I, Kyeyune F, Demers K, Ndashimye E, Kwok C, Chen PL, Rwambuya S, Poon A, Munjoma M, Chipato T, Byamugisha J, Mugenyi P, Salata RA, Morrison CS, Arts EJ. *PLoS Pathog.* 2018 Jan 18;14(1):e1006754. doi: 10.1371/journal.ppat.1006754. eCollection 2018 Jan. PMID: 29346424
326. [Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults \(BREATHER\): Extended follow-up results of a randomised, open-label, non-inferiority trial.](#) Turkova A, Moore CL, Butler K, Compagnucci A, Saïdi Y, Musiime V, Nanduudu A, Kaudha E, Cressey TR, Chalermpanmetagul S, Scott K, Harper L, Montero S, Riault Y, Bunupuradah T, Volokha A, Flynn PM, Bologna R, Ramos Amador JT, Welch SB, Nastouli E, Klein

N, Giaquinto C, Ford D, Babiker A, Gibb DM; BREATHER (PENTA 16) trial Group.
PLoS One. 2018 Apr 23;13(4):e0196239. doi: 10.1371/journal.pone.0196239.
eCollection 2018. PMID: 29684092

327. [Higher sequence diversity in the vaginal tract than in blood at early HIV-1 infection.](#)
Klein K, Nickel G, Nankya I, Kyeyune F, Demers K, Ndashimye E, Kwok C, Chen PL, Rwambuya S, Poon A, Munjoma M, Chipato T, Byamugisha J, Mugenyi P, Salata RA, Morrison CS, Arts EJ. PLoS Pathog. 2018 Jan 18;14(1):e1006754. doi: 10.1371/journal.ppat.1006754. eCollection 2018 Jan. PMID: 29346424
328. [Absence of HIV-1 Drug Resistance Mutations Supports the Use of Dolutegravir in Uganda.](#) Ndashimye E, Avino M, Kyeyune F, Nankya I, Gibson RM, Nabulime E, Poon AFY, Kityo C, Mugenyi P, Quiñones-Mateu ME, Arts EJ AIDS Res Hum Retroviruses. 2018 May;34(5):404-414. doi: 10.1089/AID.2017.0205. Epub 2018 Feb 26. PMID: 29353487.
329. [Efficacy and Safety of Switching to Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide \(E/C/F/Taf\) in Virologically Suppressed Women.](#) Hodder S, Squires K, Kityo C, Hagins D, Avihingsanon A, Kido A, Jiang S, Kulkarni R, Cheng A, Cao H. J Acquir Immune Defic Syndr. 2018 Feb 21. Doi: 10.1097/QAI.0000000000001663. Epub ahead of print

2019

330. [Microbial Translocation Does Not Drive Immune Activation in Ugandan Children Infected With HIV.](#) Fitzgerald FC, Lhomme E, Harris K, Kenny J, Doyle R, Kityo C, Shaw LP, Abongomera G, Musiime V, Cook A, Brown JR, Brooks A, Owen-Powell E, Gibb DM, Prendergast AJ, Sarah Walker A, Thiebaut R, Klein N; CHAPAS-3 Trial Team. J Infect Dis. 2019 Jan 1;219(1):89-100. doi: 10.1093/infdis/jiy495.
331. [First-line HIV treatment failures in non-B subtypes and recombinants: a cross-sectional analysis of multiple populations in Uganda.](#) Poon AFY, Ndashimye E, Avino M, Gibson R, Kityo C, Kyeyune F, Nankya I, Quiñones-Mateu ME, Arts EJ; The Ugandan Drug Resistance Study Team. AIDS Res Ther. 2019 Jan 22;16(1):3. doi: 10.1186/s12981-019-0218-2.
332. [Moving to Another World: Understanding the Impact of Clinical Trial Closure on Research Participants Living With HIV in Uganda.](#) Nalubega S, Cox K, Mugerwa H, Evans C.
J Assoc Nurses AIDS Care. 2019 Jan 17. doi: 10.1097/JNC.0000000000000057.
[Epub ahead of print]

333. [Risk factors for antiretroviral therapy \(ART\) discontinuation in a large multinational trial of early ART initiators.](#) Bansi-Matharu L, Loria GR, Cole SR, Mugerwa H, Vecino I, Lundgren J, Pulik P, Smith C, Phillips AN; INSIGHT START Study Group. *AIDS*. 2019 Mar 29. doi: 10.1097/QAD.0000000000002210. [Epub ahead of print] PMID: 30932953
334. [Inferring HIV-1 transmission networks and sources of epidemic spread in Africa with deep-sequence phylogenetic analysis.](#) Ratmann O, Grabowski MK, Hall M, Golubchik T, Wymant C, Abeler-Dörner L, Bonsall D, Hoppe A, Brown AL, de Oliveira T, Gall A, Kellam P, Pillay D, Kagaayi J, Kigozi G, Quinn TC, Wawer MJ, Laeyendecker O, Serwadda D, Gray RH, Fraser C; PANGEA Consortium and Rakai Health Sciences Program. *Nat Commun*. 2019 Mar 29;10(1):1411. doi: 10.1038/s41467-019-09139-4.
335. [Impact of Integrase Inhibition compared to non-nucleoside inhibition on HIV reservoirs in Lymphoid Tissues.](#) Rothenberger M, Nganou-Makamdop K, Kityo C, Ssali F, Chipman JG, Beilman GJ, Hoskuldsson T, Anderson J, Jasurda J, Schmidt TE, Calisto SP, Pearson H, Reimann T, David C, Perkey K, Southern P, Wietgreffe S, Helgeson E, Reilly C, Haase AT, Douek DC, Fletcher CV, Schacker TW. *J Acquir Immune Defic Syndr*. 2019 Mar 15. doi: 10.1097/QAI.0000000000002026. [Epub ahead of print]
336. [Discovery and Characterization of Bukakata orbivirus \(*Reoviridae:Orbivirus*\), a Novel Virus from a Ugandan Bat.](#) Fagre AC, Lee JS, Kityo RM, Bergren NA, Mossel EC, Nakayiki T, Nalikka B, Nyakarahuka L, Gilbert AT, Peterhans JK, Crabtree MB, Towner JS, Amman BR, Sealy TK, Schuh AJ, Nichol ST, Lutwama JJ, Miller BR, Kading RC. *Viruses*. 2019 Mar 2;11(3). pii: E209. doi: 10.3390/v11030209.
337. [Perceptions of Strategies and Intervention Approaches for HIV Self-Management among Ugandan Adolescents: A Qualitative Study.](#) Mutumba M, Mugerwa H, Musiime V, Gautam A, Nakyambadde H, Matama C, Stephenson R. *J Int Assoc Provid AIDS Care*. 2019 Jan-Dec;18:2325958218823246. doi: 10.1177/2325958218823246. PMID: 30798668
338. [Cotrimoxazole reduces systemic inflammation in HIV infection by altering the gut microbiome and immune activation.](#) Bourke CD, Gough EK, Pimundu G, Shonhai A, Berejena C, Terry L, Baumard L, Choudhry N, Karmali Y, Bwakura-Dangarembizi M, Musiime V, Lutaakome J, Kekitiinwa A, Mutasa K, Szubert AJ, Spyer MJ, Deayton JR, Glass M, Geum HM, Pardieu C, Gibb DM, Klein N, Edens TJ, Walker AS, Manges AR, Prendergast AJ. *Sci Transl Med*. 2019 Apr 3;11(486). pii: eaav0537. doi: 10.1126/scitranslmed.aav0537. PMID: 30944164

339. [Subclinical Vascular Disease in Children with HIV in Uganda is Associated with Intestinal Barrier Dysfunction.](#) Dirajlal-Fargo S, Albar Z, Bowman E, Labbato D, Sattar A, Karungi C, Longenecker CT, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA. *Clin Infect Dis*. 2019 Dec 6. pii: ciz1141. doi: 10.1093/cid/ciz1141. [Epub ahead of print] PMID: 31807748
340. [Lessons for test and treat in an antiretroviral programme after decentralisation in Uganda: a retrospective analysis of outcomes in public healthcare facilities within the Lablite project.](#) Kiwuwa-Muyingo S, Abongomera G, Mambule I, Senjovu D, Katabira E, Kityo C, Gibb DM, Ford D, Seeley J. *Int Health*. 2019 Nov 15. pii: ihz090. doi: 10.1093/inthealth/ihz090. [Epub ahead of print] PMID: 31730168
341. [Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses \(300 mg/day\) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.](#) Ross LL, Walker AS, Lou Y, Tenorio AR, Gibb DM, Double J, Gilks C, McCoig CC, Munderi P, Musoro G, Kityo CM, Grosskurth H, Hakim J, Mugenyi PN, Cutrell A, Perger T, Shaefer MS. *PLoS One*. 2019 Nov 14;14(11):e0225199. doi: 10.1371/journal.pone.0225199. eCollection 2019. PMID: 31725787
342. [Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.](#) Bajunirwe F, Akakimpa D, Tumwebaze FP, Abongomera G, Mugenyi PN, Kityo CM. *PLoS One*. 2019 Nov 6;14(11):e0211084. doi: 10.1371/journal.pone.0211084. eCollection 2019. PMID: 31693660
343. [Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide \(B/F/TAF\) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial.](#) Kityo C, Hagins D, Koenig E, Avihingsanon A, Chetchotisakd P, Supparatpinyo K, Gankina N, Pokrovsky V, Voronin E, Stephens JL, DeJesus E, Wang H, Acosta RK, Cao H, Quirk E, Martin H, Makadzange T. *J Acquir Immune Defic Syndr*. 2019 Nov 1;82(3):321-328. doi: 10.1097/QAI.0000000000002137. PMID: 31609930
344. [HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans.](#) Buggie J, Yun L, Hung CL, Kityo C, Mirembe G, Erem G, Truong T, Ssinabulya I, Tang WHW, Hoit BD, McComsey GA, Longenecker CT. *Heart*. 2019 Sep 19. pii: heartjnl-2019-315346. doi: 10.1136/heartjnl-2019-315346. [Epub ahead of print] PMID: 31537637
345. [Long-term virological outcomes, failure and acquired resistance in a large cohort of Ugandan children.](#) Huibers MHW, Kityo C, Boerma RS, Kaudha E, Sigaloff KCE, Balinda SN, Bertagnolio S, Nakanjako R, Mugenyi P, Calis JCJ, Boele van Hensbroek M, Rinke de Wit TF. *J Antimicrob Chemother*. 2019 Oct 1;74(10):3035-3043. doi: 10.1093/jac/dkz266. PMID: 31289811

346. [Altered intestinal permeability and fungal translocation in Ugandan children with HIV](#). Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, McComsey GA. Clin Infect Dis. 2019 Jul 1. pii: ciz561. doi: 10.1093/cid/ciz561. [Epub ahead of print] PMID: 31260509
347. [Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial](#). Ekenberg C, Tang MH, Zucco AG, Murray DD, MacPherson CR, Hu X, Sherman BT, Losso MH, Wood R, Paredes R, Molina JM, Helleberg M, Jina N, Kityo CM, Florence E, Polizzotto MN, Neaton JD, Lane HC, Lundgren JD. J Infect Dis. 2019 Sep 13;220(8):1325-1334. doi: 10.1093/infdis/jiz294. PMID:31219150
348. [Coronary artery calcium, HIV and inflammation in Uganda compared with the USA](#). Alencherry B, Erem G, Mirembe G, Ssinabulya I, Yun CH, Hung CL, Siedner MJ, Bittencourt M, Kityo C, McComsey GA, Longenecker CT. Open Heart. 2019 May 22;6(1):e001046. doi: 10.1136/openhrt-2019-001046. eCollection 2019. PMID:31218009
349. [Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy](#). Kroeze S, Wit FW, Rossouw TM, Steel HC, Kityo CM, Siwale M, Akanmu S, Mandaliya K, de Jager M, Ondoa P, Reiss P, Rinke de Wit TF, Kootstra N, Hamers RL. J Infect Dis. 2019 Aug 9;220(6):1029-1033. doi: 10.1093/infdis/jiz252. PMID: 31086991
350. [Mapping the medical outcomes study HIV health survey \(MOS-HIV\) to the EuroQoL 5 Dimension \(EQ-5D-3 L\) utility index](#). Shi Y, Thompson J, Walker AS, Paton NI, Cheung YB; EARNEST Trial Team. Health Qual Life Outcomes. 2019 May 10;17(1):83. doi: 10.1186/s12955-019-1135-8. PMID: 31077251
351. [Evolution of Protease Inhibitor Resistance in Human Immunodeficiency Virus Type 1 Infected Patients Failing Protease Inhibitor Monotherapy as Second-line Therapy in Low-income Countries: An Observational Analysis Within the EARNEST Randomized Trial](#). Thompson JA, Kityo C, Dunn D, Hoppe A, Ndashimye E, Hakim J, Kambugu A, van Oosterhout JJ, Arribas J, Mugenyi P, Walker AS, Paton NI; Europe–Africa Research Network for Evaluation of Second line Therapy (EARNEST) Trial Team . Clin Infect Dis. 2019 Mar 19;68(7):1184-1192. doi: 10.1093/cid/ciy589. PMID: 30060027
352. [Prevalence of non-communicable diseases among HIV positive patients on antiretroviral therapy at joint clinical research centre, Lubowa, Uganda](#). Kansime S, Mwesigire D, Mugerwa H. PLoS One. 2019 Aug 9;14(8):e0221022. doi: 10.1371/journal.pone.0221022. eCollection 2019. PMID: 31398244

353. [Third-line antiretroviral therapy in low-income and middle-income countries \(ACTG A5288\): a prospective strategy study.](#) Grinsztejn B, Hughes MD, Ritz J, Salata R, Mugenyi P, Hogg E, Wieclaw L, Gross R, Godfrey C, Cardoso SW, Bukuru A, Makanga M, Faesen S, Mave V, Wangari Ndege B, Nerette Fontain S, Samaneka W, Secours R, van Schalkwyk M, Mngqibisa R, Mohapi L, Valencia J, Sugandhavesa P, Montalban E, Avihingsanon A, Santos BR, Kumarasamy N, Kanyama C, Schooley RT, Mellors JW, Wallis CL, Collier AC; A5288 Team. *Lancet HIV*. 2019 Sep;6(9):e588-e600. doi: 10.1016/S2352-3018(19)30146-8. Epub 2019 Jul 29. PMID: 31371262
354. [Perceptions of HIV Self-Management Roles and Challenges in Adolescents, Caregivers, and Health Care Providers.](#) Mutumba M, Musiime V, Mugerwa H, Nakyambadde H, Gautam A, Matama C, Stephenson R. *J Assoc Nurses AIDS Care*. 2019 Jul-Aug;30(4):415-427. doi: 10.1097/JNC.000000000000011. PMID: 31241506
355. [Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda.](#) Dirajlal-Fargo S, Shan L, Sattar A, Bowman E, Gabriel J, Kulkarni M, Funderburg N, Nazzinda R, Musiime V, McComsey GA. *HIV Med*. 2019 Oct 23. doi: 10.1111/hiv.12808. [Epub ahead of print] PMID: 31642582
356. [Prioritising the most needed paediatric antiretroviral formulations: the PADO4 list.](#) Penazzato M, Townsend CL, Rakhmanina N, Cheng Y, Archary M, Cressey TR, Kim MH, Musiime V, Turkova A, Ruel TD, Rabie H, Sugandhi N, Rojo P, Doherty M, Abrams EJ; PADO4 participants. *Lancet HIV*. 2019 Sep;6(9):e623-e631. doi: 10.1016/S2352-3018(19)30193-6. Review. PMID: 31498110
357. [Two-way mobile phone intervention compared with standard-of-care adherence support after second-line antiretroviral therapy failure: a multinational, randomised controlled trial.](#) Gross R, Ritz J, Hughes MD, Salata R, Mugenyi P, Hogg E, Wieclaw L, Godfrey C, Wallis CL, Mellors JW, Mudhune VO, Badal-Faesen S, Grinsztejn B, Collier AC. *Lancet Digit Health*. 2019 May;1(1):e26-e34. doi: 10.1016/S2589-7500(19)30006-8. Epub 2019 May 6. PMID: 31528850

2020

358. [The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection](#) Matthew Peters, [Seunghee Margevicius](#), [Cissy Kityo](#), [Grace Mirembe](#), [Jonathan Buggy](#), [Ellen Brinza](#), [Mark Schluchter](#), [Chun-Ho Yun](#), [Chung-Lieh Hung](#), [Grace A McComsey](#), [Chris T Longenecker](#) *J Acquir Immune Defic Syndr*. 2021 Jan 1;86(1):104-109 PMID: 33044321.

359. [Micronutrients, Metabolic Complications and Inflammation in Ugandan Children with HIV](#). Dirajlal-Fargo S, Shan L, Sattar A, Kulkarni M, Bowman E, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, Mccomsey GA. *J Pediatr Gastroenterol Nutr*. 2020 Jan 14. doi: 10.1097/MPG.0000000000002630. [Epub ahead of print] PMID:31939864
360. [HIV and pericardial fat are associated with abnormal cardiac structure and function among Ugandans](#). Buggey J, Yun L, Hung CL, Kityo C, Mirembe G, Erem G, Truong T, Ssinabulya I, Tang WHW, Hoit BD, McComsey GA, Longenecker CT. *Heart*. 2020 Jan; 106(2):147-153. doi: 10.1136/heartjnl-2019-315346. PMID:31537637
361. [Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda](#). Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I. *AIDS Res Ther*. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7. PMID: 32005262
362. [New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings](#). David Dunn, Huw Price, Tobias Vudriko^c, Cissy Kityo, Godfrey Musoro, James Hakim, Charles Gilks, Pontiano Kaleebu, Deenan Pillay, Richard Gilson, DART Virology Group. *J Acquir Immune Defic Syndr*. 2021. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517
PMID: 33306565
363. [Comparison of HIV drug resistance profiles across HIV-1 subtypes A and D for patients receiving a tenofovir-based and zidovudine-based first line regimens in Uganda](#). Ayitewala A, Kyeyune F, Ainembabazi P, Nabulime E, Kato CD, Nankya I. *AIDS Res Ther*. 2020 Jan 31;17(1):2. doi: 10.1186/s12981-020-0258-7. PMID: 32005262
364. [Increased monocyte and T-cell activation in treated HIV+ ugandan children: associations with gut alteration and HIV factors](#). Dirajlal-Fargo S, Albar Z, Bowman E, Labbato D, Sattar A, Karungi C, Nazzinda R, Funderburg N, Kityo C, Musiime V, McComsey GA. *AIDS*. 2020 Feb 17. doi: 10.1097/QAD.0000000000002505. [Epub ahead of print] PMID:32073452
365. [The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa](#). Walker SM, Cox E, Revill P, Musiime V, Bwakura-

Dangarembizi M, Mallewa J, Cheruiyot P, Maitland K, Ford N, Gibb DM, Walker AS, Soares M; REALITY trial team. *J Int AIDS Soc.* 2020 Mar;23(3):e25469. doi: 10.1002/jia2.25469. PMID: 32219991 Free PMC article.

366. [The cost-effectiveness of prophylaxis strategies for individuals with advanced HIV starting treatment in Africa](#) Simon M Walker, Edward Cox, Paul Revill, Victor Musiime, MutsaBwakura-Dangarembizi, Jane Mallewa, Priscilla Cheruiyot, Kathryn Maitland, Nathan Ford, Diana M Gibb, A Sarah Walker, Marta Soares, the REALITY trial team *J Int AIDS Soc.* 2020 Mar; 23(3): e25469. Published online 2020 Mar 27. doi: 10.1002/jia2.25469
367. [Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus](#). Dirajlal-Fargo S, El-Kamari V, Weiner L, Shan L, Sattar A, Kulkarni M, Funderburg N, Nazzinda R, Karungi C, Kityo C, Musiime V, McComsey GA. *Clin Infect Dis.* 2020 May 23;70(11):2413-2422. doi: 10.1093/cid/ciz561. PMID: 31260509 Free PMC article.
368. [Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda](#). Dirajlal-Fargo S, Albar Z, Sattar A, Kulkarni M, Bowman E, Funderburg N, Nazzinda R, Kityo C, Musiime V, McComsey GA. *AIDS Care.* 2020 Jun 15:1-6. doi: 10.1080/09540121.2020.1776822. Online ahead of print. PMID: 32539474
369. [Recombination Analysis of Near Full-Length HIV-1 Sequences and the Identification of a Potential New Circulating Recombinant Form from Rakai, Uganda](#). Capoferri AA, Lamers SL, Grabowski MK, Rose R, Wawer MJ, Serwadda D, Gray RH, Quinn TC, Kigozi G, Kagaayi J, Laeyendecker O; Rakai Health Sciences Program and the PANGEA Consortium. *AIDS Res Hum Retroviruses.* 2020 Jun; 36(6):467-474. doi: 10.1089/AID.2019.0150. Epub 2020 PMID: 31914792
370. [Marginal structural models for repeated measures where intercept and slope are correlated: An application exploring the benefit of nutritional supplements on weight gain in HIV-infected children initiating antiretroviral therapy](#) Ruth E. Farmer, Rhian Daniel, Deborah Ford, Adrian Cook, Victor Musiime, MutsaBwakura-Dangarembizi, Diana M. Gibb, Andrew J. Prendergast, A. Sarah Walker, on behalf of the ARROW trial team *PLoS One.* 2020; 15(7): e0233877. Published online 2020 Jul 9. doi: 10.1371/journal.pone.0233877
371. [Pharmacokinetics of antiretroviral and tuberculosis drugs in children with HIV/TB co-infection: a systematic review](#). Jacobs TG, Svensson EM, Musiime V, Rojo P, Dooley KE, McIlleron H, Aarnoutse RE, Burger DM, Turkova A, Colbers A; WHO Paediatric Antiretroviral Working Group. *J Antimicrob Chemother.* 2020 Aug 12:dkaa328. doi: 10.1093/jac/dkaa328. Online ahead of print. PMID: 32785712

372. [Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial.](#) Bollen PDJ, Moore CL, Mujuru HA, Makumbi S, Kekitiinwa AR, Kaudha E, Parker A, Musoro G, Nanduudu A, Lugemwa A, Amuge P, Hakim JG, Rojo P, Giaquinto C, Colbers A, Gibb DM, Ford D, Turkova A, Burger DM; ODYSSEY trial team. *Lancet HIV*. 2020 Aug; 7(8):e533-e544. doi: 10.1016/S2352-3018(20)30189-2. PMID: 32763217; PMCID: PMC7445428.
373. [The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.](#) Inzaule SC, Bertagnolio S, Kityo CM, Siwale M, Akanmu S, Wellington M, de Jager M, Ive P, Mandaliya K, Stevens W, Boender TS, Ondo P, Sigaloff KCE, Rinke de Wit TF, Hamers RL. *AIDS*. 2020 Aug 1;34(10):1559-1566. doi: 10.1097/QAD.0000000000002588. PMID: 32675566.
374. ["Because we all have to grow up": supporting adolescents in Uganda to develop core competencies to transition towards managing their HIV more independently.](#) Lanyon C, Seeley J, Namukwaya S, Musiime V, Paparini S, Nakyambadde H, Matama C, Turkova A, Bernays S.J *Int AIDS Soc*. 2020 Sep;23 Suppl 5(Suppl 5):e25552. doi: 10.1002/jia2.25552.PMID: 32869514
375. [Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.](#)[Sarah L Pett](#), [Maira Spyer](#), [Lewis J Haddow](#), [Ruth Nhema](#), [Laura A Benjamin](#), [Grace Najjuka](#), [Sithembile Bilima](#), [Ibrahim Daud](#), [Godfrey Musoro](#), [Juliet Kitabalwa](#), [George Selemani](#), [Salome Kandie](#), [K Magut Cornelius](#), [Chrispus Katemba](#), [Jay A Berkley](#), [Amin S Hassan](#), [Cissy Kityo](#), [James Hakim](#), [Robert S Heyderman](#), [Diana M Gibb](#), [A Sarah Walker](#), [REALITY trial team](#) *JAIDS*, September 2020 PMID: 33306556
376. [Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda.](#) Dirajlal-Fargo S, Shan L, Sattar A, Bowman E, Gabriel J, Kulkarni M, Funderburg N, Nazzinda R, Musiime V, McComsey GA. *HIV Med*. 2020 Feb;21(2):119-127. doi: 10.1111/hiv.12808. Epub 2019 Oct 23. PMID: 31642582
377. [Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection.](#) Peters M, Margevicius S, Kityo C, Mirembe G, Bugey J, Brinza E, Schluchter M, Yun C, Hung C, McComsey G, Longenecker C. *J Acquir Immune Defic Syndr*. 2020 Dec. PMID: 33044321.
378. [Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from](#)

patients failing raltegravir in Uganda. Emmanuel Ndashimye, Mariano Avino, Abayomi S Olabode, Art F Y Poon, Richard M Gibson, Yue Li, Adam Meadows, Christine Tan, Paul S Reyes, Cissy M Kityo, Fred Kyeyune, Immaculate Nankya, Miguel E Quiñones-Mateu, Eric J Arts. J Antimicrob Chemother. 2020 Dec 1;75(12):3525-3533. doi: 10.1093/jac/dkaa355. PMID: 32853364

379. Monocyte Activation in Persons Living with HIV and Tuberculosis Coinfection Moises A. Huaman, Steven M. Juchnowski, David A. Zidar, Cissy M. Kityo, Sophie Nalukwago, Rashidah Nazzinda, Carl J. Fichtenbaum, Chris T. Longenecker AIDS. Dec. 2020. PMID: 33252496
380. Failure is not an Option: Barriers to HIV Treatment Adherence in Kampala, Uganda Corresponding author: Gabrielle Bruser, Ritah Katasi, Lily Ziyue Zhang, Miriam Namasinga, Eric Arts, Cissy Kityo, Isaac Luginaah. Health Place. 2020. Dec 1;67:102481. Doi: 10.1016. PMID: 33276263
381. A Mixed Methods, Observational Investigation of Physical Activity, Exercise, and Diet Among Older Ugandans Living With and Without Chronic HIV Infection. Wright CH, Longenecker CT, Nazzindah R, Kityo C, Najjuuko T, Taylor K, Rentrop CR, Webel A. J Assoc Nurses AIDS Care. 2020 Dec 2. doi: 10.1097/JNC.000000000000221. Epub ahead of print. PMID: 33273157.
382. The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection Matthew Peters, Seunghee Margevicius, Cissy Kityo, Grace Mirembe, Jonathan Buggey, Ellen Brinza, Mark Schluchter, Chun-Ho Yun, Chung-Lieh Hung, Grace A McComsey, Chris T Longenecker J Acquir Immune Defic Syndr. 2021 Jan 1;86(1):104-109 PMID: 33044321.

2021 (so far)

383. Latent Tuberculosis Infection and Subclinical Coronary Atherosclerosis in Peru and Uganda. Huaman MA, De Cecco CN, Bittencourt MS, Ticona E, Kityo C, Isabel B, Nalukwago S, Nazzinda R, Ticona C, Azañero R, Zhang B, Carey F, Thomas HR, Sterling TR, Carl FJ, Chris LT. Clin Infect Dis. 2021 Jan 3;ciaa1934. doi: 10.1093/cid/ciaa1934. Online ahead of print. PMID: 33388766
384. Failure is not an option: Barriers to HIV treatment adherence in Kampala, Uganda Bruser G, Katasi R, Zhang LZ, Namasinga M, Arts E, Kityo C, Luginaah I. Health Place. 2021 Jan;67:102481. doi: 10.1016/j.healthplace.2020.102481. Epub 2020 Dec 1. PMID: 33276263.

385. The Association of Kidney Disease with Abnormal Cardiac Structure and Function among Ugandans with HIV Infection Matthew Peters, Seunghee Margevicius, Cissy Kityo, Grace Mirembe, Jonathan Buggey, Ellen Brinza, Mark Schluchter, Chun-Ho Yun, Chung-Lieh Hung, Grace A McComsey, Chris T Longenecker JAcquir Immune Defic Syndr. 2021 Jan 1;86(1):104-109 doi: 10.1097/QAI.0000000000002529.PMID: 33044321
386. [New Insights on Long-Term Hepatitis B Virus Responses in HIV-Hepatitis B virus Co-infected Patients: Implications for Antiretroviral Management in Hepatitis B virus-Endemic Settings.](#) Dunn D, Price H, Vudriko T, Kityo C, Musoro G, Hakim J, Gilks C, Kaleebu P, Pillay D, Gilson R; DART Virology Group. JAcquir Immune Defic Syndr. 2021 Jan 1;86(1):98-103. doi: 10.1097/QAI.0000000000002517.PMID: 33306565
387. [ODYSSEY clinical trial design: a randomized global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.](#) Moore CL, Turkova A, Mujuru H, Kekitiinwa A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saïdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team. BMC Infect Dis. 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6.PMID: 33446115 Free PMC article. Clinical Trial.
388. [Factors associated with virological non-suppression among HIV-positive children receiving antiretroviral therapy at the Joint Clinical Research Centre in Lubowa, Kampala Uganda.](#) Nabukeera S, Kagaayi J, Makumbi FE, Mugerwa H, Matovu JKB. PLoS One. 2021 Jan 27;16(1):e0246140. doi: 10.1371/journal.pone.0246140. eCollection 2021.PMID: 33503074 Free PMC article.
389. [Deep Gene Sequence Cluster Analyses of Multi-Virus-Infected Mucosal Tissue Reveal Enhanced Transmission of Acute HIV-1.](#) Klein K, Nankya I, Nickel G, Ratcliff AN, Meadows AAJ, Hathaway N, Bailey JA, Stieh DJ, Cheeseman HM, Carias AM, Lobritz MA, Mann JFS, Gao Y, Hope TJ, Shattock RJ, Arts EJ. Klein K, et al. J Virol. 2021 Jan 13;95(3):e01737-20. doi: 10.1128/JVI.01737-20. Print 2021 Jan 13. J Virol. 2021.PMID: 33177204 Free article.
390. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing. Moore CL, Turkova A, Mujuru H, Kekitiinwa

- A, Lugemwa A, Kityo CM, Barlow-Mosha LN, Cressey TR, Violari A, Variava E, Cotton MF, Archary M, Compagnucci A, Puthanakit T, Behuhuma O, Saïdi Y, Hakim J, Amuge P, Atwine L, Musiime V, Burger DM, Shakeshaft C, Giaquinto C, Rojo P, Gibb DM, Ford D; ODYSSEY Trial Team. [BMC Infect Dis.](#) 2021 Jan 4;21(1):5. doi: 10.1186/s12879-020-05672-6.PMID: 33446115 Free PMC article. Clinical Trial.
391. [Urine LAM Testing in Advanced HIV Positive Adults in a Trial of Empiric TB Therapy.](#) Matoga MM, Bisson GP, Gupta A, Miyahara S, Sun X, Fry C, Manabe YC, Kumwenda J, Cecilia K, Nyirenda M, Ngongondo M, Mbewe A, Lagat D, Wallis C, Mugerwa H, HosseinipourMC. Matoga MM, et al. [Clin Infect Dis.](#) 2021 Feb 26:ciab179. doi: 10.1093/cid/ciab179. Online ahead of print. [Clin Infect Dis.](#) 2021.PMID: 33638976
392. [Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.](#) Pett SL, Spyer M, Haddow LJ, Nhema R, Benjamin LA, Najjuka G, Bilima S, Daud I, Musoro G, Kitabalwa J, Selemani G, Kandie S, Cornelius KM, Katemba C, Berkley JA, Hassan AS, Kityo C, Hakim J, Heyderman RS, Gibb DM, Walker AS; REALITY trial team. [AIDS.](#) 2021 Mar 15;35(4):585-594. doi: 10.1097/QAD.0000000000002781.PMID: 33306556
393. [Monocyte activation in persons living with HIV and tuberculosis coinfection.](#) Huaman MA, Juchnowski SM, Zidar DA, Kityo CM, Nalukwago S, Nazzinda R, Fichtenbaum CJ, Longenecker CT. [AIDS.](#) 2021 Mar 1;35(3):447-452. doi: 10.1097/QAD.0000000000002766.PMID: 33252496
394. [A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19.](#) ACTIV-3/TICO LY-CoV555 Study Group, Lundgren JD, Grund B, Barkauskas CE, Holland TL, Gottlieb RL, Sandkovsky U, Brown SM, Knowlton KU, Self WH, Files DC, Jain MK, Benfield T, Bowdish ME, Leshnowar BG, Baker JV, Jensen JU, Gardner EM, Ginde AA, Harris ES, Johansen IS, Markowitz N, Matthay MA, Østergaard L, Chang CC, Davey VJ, Goodman A, Higgs ES, Murray DD, Murray TA, Paredes R, Parmar MKB, Phillips AN, Reilly C, Sharma S, Dewar RL, Teitelbaum M, Wentworth D, Cao H, Klekotka P, Babiker AG, Gelijns AC, Kan VL, Polizzotto MN, Thompson BT, Lane HC, Neaton JD. [N Engl J Med.](#) 2021 Mar 11;384(10):905-914. doi: 10.1056/NEJMoa2033130. Epub 2020 Dec 22.PMID: 33356051 Free PMC article. Clinical Trial
395. Lipidome association with vascular disease and inflammation in HIV+ Ugandan children. Dirajlal-Fargo S, Sattar A, Yu J, Albar Z, Chaves FC, Riedl K, Kityo C, Bowman E, Mccomsey GA, Funderburg N. [AIDS.](#) 2021 Apr 19. doi: 10.1097/QAD.0000000000002923. Epub ahead of print. PMID: 33878042.

396. Facilitated transition in HIV drug trial closure: a conceptual model for HIV post-trial care. Nalubega S, Cox K, Mugerwa H, Evans C. *PLoS One*. 2021 Apr 29;16(4):e0250698. doi: 10.1371/journal.pone.0250698. PMID: 33914783; PMCID: PMC8084151.
397. Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda. Musana H, Ssensamba JT, Nakafeero M, Mugerwa H, Kiweewa FM, Serwadda D, Ssali F. *AIDS Res Ther*. 2021 Apr 21;18(1):17. doi: 10.1186/s12981-021-00338-y. PMID: 33882938; PMCID: PMC8059285.
398. Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium.. *N Engl J Med*. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. PMID: 33951360.
399. Sex, HIV-status, and Measures of Cardiac Stress and Fibrosis in Uganda. Kipke J, Margevicius S, Kityo C, Mirembe G, Buggey J, Yun CH, Hung CL, McComsey GA, Longenecker CT. *J Am Heart Assoc*. 2021 [;10(11):e018767. doi: 10.1161/JAHA.120.018767. Epub 2021 May 15. PMID: 33998251.
400. Sex, HIV Status, and Measures of Cardiac Stress and Fibrosis in Uganda. Kipke J, Margevicius S, Kityo C, Mirembe G, Buggey J, Yun CH, Hung CL, McComsey GA, Longenecker CT.. *J Am Heart Assoc*. 2021 Jun;10(11):e018767. doi: 10.1161/JAHA.120.018767. Epub 2021 May 15. PMID: 33998251.
401. Feasibility of collecting and processing of COVID-19 convalescent plasma for treatment of COVID-19 in Uganda. Muttamba W, Lusiba J, Namakula LO, Byakika-Kibwika P, Ssali F, Ddungu H, Mugenyi L, Kiwanuka N, Sekibira R, Kityo C, Keyune D, Acana S, Musinguzi A, Masasi A, Byamugisha J, Mpanju D, Musoki WJ, Tukamuhebwa HA, Nakwagala F, Bagaya BS, Kayongo A, Kimuli I, Nantanda R, Katagira W, Buregyeya E, Byanyima R, Byarugaba B, Siddharthan T, Mwebesa H, Charles O, Joloba ML, Bazeyo W, Kirenga B.. *PLoS One*. 2021 Jun 17;16(6):e0252306. doi: 10.1371/journal.pone.0252306. PMID: 34138909; PMCID: PMC8211202.
402. Translocated microbiome composition determines immunological outcome in treated HIV infection Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, Chipman JG, Beilman GJ, Hoskuldsson T, Fourati S, Schmidt TE,

Arumugam S, Lima NS, Moon D, Callisto S, Schoephoerster J, Tomalka J, Mugenyi P, Ssali F, Muloma P, Ssendendo P, Leda AR, Cheu RK, Flynn JK, Morou A, Brunet-Ratnasingham E, Rodriguez B, Lederman MM, Kaufmann DE, Klatt NR, Kityo C, Brenchley JM, Schacker TW, Sekaly RP, Douek DC.. *Cell*. 2021 Jun 30:S0092-8674(21)00653-X. doi: 10.1016/j.cell.2021.05.023. Epub ahead of print. PMID: 34237254.

403. Ethical and practical considerations in HIV drug trial closure: perspectives of research staff in Uganda: Sylvia Nalubega, Karen Cox, Henry Mugerwa, Catrins Evans, [sagepub.com/journals-permissions](https://www.sagepub.com/journals-permissions). 2021 Jul 10: DOI: 10.1177/17470161211030971
404. [Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV](#). Paton NI, Musaazi J, Kityo C, Walimbwa S, Hoppe A, Balyegisawa A, Kaimal A, Mirembe G, Tukamushabe P, Ategeka G, Hakim J, Mugerwa H, Siika A, Asienzo J, Castelnuovo B, Kiragga A, Kambugu A; NADIA Trial Team. *N Engl J Med*. 2021 Jul 22;385(4):330-341. doi: 10.1056/NEJMoa2101609. PMID: 34289276
405. [Clinical Outcomes, Echocardiographic Findings, and Care Quality Metrics for People Living with HIV and Rheumatic Heart Disease in Uganda](#). Chang AY, Rwebembera J, Bendavid E, Okello E, Barry M, Beaton AZ, Haefele C, Webel AR, Kityo C, Longenecker CT. *Clin Infect Dis*. 2021 Aug 12:ciab681. doi: 10.1093/cid/ciab681. Online ahead of print. PMID: 34382644
406. [High-level resistance to bicitgravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations](#). Ndashimye E, Li Y, Reyes PS, Avino M, Olabode AS, Kityo CM, Kyeyune F, Nankya I, Quiñones-Mateu ME, Barr SD, Arts EJ. *J Antimicrob Chemother*. 2021 Aug 28:dkab276. doi: 10.1093/jac/dkab276. Online ahead of print. PMID: 34453542